 
 
 
 
A PILOT TRIAL OF IPILIMUMAB WITH NIVOLUMAB FOR 
PATIENTS WITH RESECTED STAGES IIIB/IIIC/ IV 
MEL ANOMA  
 
 
Regulatory Sponsor:        Perlmutter Cancer Center and NYU Langone Medical Center  
                                         160 East 34th Street  
                                         New York, NY 10016  
 
 
Funding:                           Bristol Myer s Squibb  
                                          345 Park Ave  
                                          New York, NY 10154  
 
Study Product:                  Nivolumab  (NSC 748726)  
                                          Ipilimumab (NSC 732442)  
 
 
Protocol Number:             S16-00098  
 
 
IND Number:                   Exemption Granted by FDA  10-2016  
 
 
Investigators:                    Jeffrey S. Weber, MD, PhD  
                                          Laura and Isaac Perlmutter Cancer Center  
                                          160 E. 34th Street  
                                          New York, NY 10016  
                                          Tel:  212 -263-9333  
                                          Fax:  212 -263-9190  
                                          Email:  Jeffrey. Weber2@nyumc.org  
 
 
Investigational Agents:  
 
NIVOLUMAB (NSC 748726 – Approved agent, supplied by BMS)  
Ipilimumab (NSC 732442) – Approved agent, supplied by BMS  
 
 
Initial version:  [12/17/2015 ] 
Amended:  [7/28/2016 ] 
Amended:  [8/26/ 2016] 
Amended:        [9/28/2016]  
Amended :       [10/15/2016]  
Amended :        [11/1/2016]  
Amended :  [11/10/2017 ]Clinical Research Protocol 
ProtocolProProtocol  
[STUDY_ID_REMOVED]
NCT Number:
 
 
 TABLE OF CONTENTS  
SYNOPSIS  ................................ ................................ ................................ ................................ ......5 
ABBREVIATION  ................................ ................................ ................................ .......................... 9 
1. INTRODUCTION AND RATIONALE  ................................ ................................ ............... 16 
1.1. Disease Description  ................................ ................................ ................................ .....16 
1.2. Principles of the Proposed Therapies  ................................ ................................ ........... 16 
1.2.1.  NIVOLUMAB  ................................ ................................ .............................. 17 
1.2.2.  Ipilimumab  ................................ ................................ ................................ ....18 
1.3. Preclinical Summary of NIVOLUMAB  ................................ ................................ ......18 
1.4. Clinical Summary  ................................ ................................ ................................ ........ 19 
1.4.1.  NIVOLUMAB  ................................ ................................ .............................. 20 
1.4.2.  Rationale for the Original NIVOLUMAB + Peptide Vaccine Clinical 
Study  ................................ ................................ ................................ ............. 20 
1.4.3       Rationale for the NIVOLUMAB + Ipilimumab Clinical Study  ................... 22 
1.4.4       Rationale for the Evaluation of PD -L1 Expression As a Biomarker  ............ 23 
1.4.5       Rationale for Flat Dosing of NIVOLUMAB  ................................ ................ 24 
STUD Y OBJECTIVES  ................................ ................................ ................................ ................ 24 
1.5. Primary Objective  ................................ ................................ ................................ ........ 24 
1.6. Secondary Objectives ................................ ................................ ................................ ...24 
2. OVERVIEW OF STUDY DESIGN  ................................ ................................ ..................... 24 
2.1. General Design and Study Schema  ................................ ................................ .............. 24 
2.2. Primary Endpoint  ................................ ................................ ................................ ......... 25 
2.3. Secondary Endpoint  ................................ ................................ ................................ .....25 
2.4. Benefit/risk ethical assessment  ................................ ................................ .................... 25 
NIVOLUMAB  ................................ ................................ .............................. 25 
2.5. Study Duratio n ................................ ................................ ................................ ............. 27 
3. STUDY POPULATION  ................................ ................................ ................................ ........ 27 
3.1. Inclusion Criteria  ................................ ................................ ................................ ......... 27 
3.2. Exclusion Criteria  ................................ ................................ ................................ ........ 29 
3.3. Inclusion of Women and Minorities  ................................ ................................ ............ 30 
3.4. Subject Recruitment and Screening  ................................ ................................ ............. 30 
 3.4.1  Informed Consent ................................ ................................ ............................... 32 
 3.4.2  Documentation of Consent  ................................ ................................ ................ 33 
3.4.3  Demographics/Medical History/Current Medical Condition/Laboratory  
Abnorm alities  ................................ ................................ ................................ ............... 33 
3.4.4  Review Inclusion/Exclusion riteria Including Concurrent Medications  ............ 33 
3.4.5  Registration Procedures  ................................ ................................ ..................... 33 
3.4.6  Early Discontinuation Criteria and Procedures ................................ .................. 34 
4. TREATMENTS ................................ ................................ ................................ ...................... 34 
4.1. Description of NIVOLUMAB with ipilimumab Treatment  ................................ ........ 34 
4.2. Treatment Regimen  ................................ ................................ ................................ ......34 
 4.2.1 Toxicity Management  ................................ ................................ ......................... 35 
4.2.1.1.  Management: ................................ ................................ .................. 34 
Protocol S16 -00098  Confidential  Page 2 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 4.2.1.2.  Dose Delay:  ................................ ................................ .................... 35 
4.2.1.3.  Discontinuation  ................................ ................................ .............. 36 
4.2.2.  Infusion Reactions  ................................ ................................ ........................ 38 
4.2.3.  Treatment Reactions:  Definitions, Monitoring, and Management  .............. 39 
4.2.4.  Dose Limiting Toxicit y:  Definition, Monitoring, Management  .................. 40 
4.2.4.1.  Definition  ................................ ................................ ....................... 40 
4.2.5.  Stopping Rules for Dose -limiting Toxicity ................................ ................... 40 
4.2.5.1.  Other Stopping Rules During Enrollment ................................ ......41 
4.2.6.  Stopping Rules for Clinical Deterioration  ................................ .................... 41 
4.3. Method for Assigning Subjects to Treatment group  ................................ .................... 41 
4.4. Preparation and Administration of Study Drug  ................................ ........................... 42 
5.4.1  Preparation  ................................ ................................ ..................... 42 
4.5. Subject Compliance Monitoring  ................................ ................................ .................. 43 
4.6. Concomitant Therapy ................................ ................................ ................................ ...43 
4.6.1. Permitted Therapy  ................................ ................................ ......................... 43 
4.6.2.  Prohibited Therapy ................................ ................................ ........................ 44 
4.7. Packaging and Labeling  ................................ ................................ ............................... 44 
4.8. Storage  ................................ ................................ ................................ ......................... 44 
4.8.1.  Drug Accountability ................................ ................................ ...................... 45 
4.9. Replacement of Subjects  ................................ ................................ .............................. 45 
5. Study procedures/evaluations  ................................ ................................ ............................... 45 
5.1. Screening Procedures  ................................ ................................ ................................ ...45 
5.1.1.  Physical Examination ................................ ................................ .................... 45 
5.1.2.  Vital Signs  ................................ ................................ ................................ .....45 
5.1.3.  Performance Status Assessment  ................................ ................................ ...46 
5.1.4.  Safety  ................................ ................................ ................................ ............ 46 
5.1.5.  Adverse Events and Concomitant Medications  ................................ ............ 46 
5.1.6.  Clinical Laboratory Tests  ................................ ................................ .............. 46 
5.1.6.1.  Chemistry  ................................ ................................ ....................... 48 
5.1.6.2.  Hematology  ................................ ................................ .................... 48 
5.1.6.3.  Urinalysis  ................................ ................................ ....................... 48 
5.1.6.4.  Other  ................................ ................................ .............................. 48 
5.1.7.  Electrocardiogram  ................................ ................................ ......................... 49 
5.2. Chest Radiograph  ................................ ................................ ................................ ......... 50 
5.3. Immunology  ................................ ................................ ................................ ................. 50 
5.4. Efficacy  ................................ ................................ ................................ ........................ 51 
5.5. Subject Completion/Early Discontinuation  ................................ ................................ .51 
5.6. Research Specimen Procedures  ................................ ................................ ................... 52 
5.6.1.  Tumor Tissue Specimens  ................................ ................................ .............. 52 
5.6.2.  Research Blood Samples ................................ ................................ ............... 52 
5.6.3.  Analysis of Immunological Response  ................................ .......................... 52 
6. Statistical plan  ................................ ................................ ................................ ........................ 52 
6.1. Sample Size Determination ................................ ................................ .......................... 52 
6.2. Study Population  ................................ ................................ ................................ .......... 52 
6.2.1.  Safety Population  ................................ ................................ .......................... 52 
6.2.2.  Evaluable Population  ................................ ................................ .................... 53 
Protocol S16 -00098  Confidential  Page 3 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 6.3. Statistical Analysis  ................................ ................................ ................................ .......53 
6.3.1. Demographics and Baseline Characteristics  ................................ ................. 53 
6.3.2.  Concomitant Medication  ................................ ................................ ............... 53 
6.3.3.  Safety  ................................ ................................ ................................ ............ 53 
6.3.4.  Immunol ogy Parameters  ................................ ................................ ............... 54 
6.3.4.1.  T-cell Proliferation  ................................ ................................ ......... 55 
6.4. Missing Data Handling  ................................ ................................ ................................ 55 
6.5. Statistical Software  ................................ ................................ ................................ ......55 
SAfety and ADVERSE EVENT REPORTING  ................................ ................................ ........ 55 
6.6. Definitions ................................ ................................ ................................ .................... 55 
6.7. Serious Adverse Events  ................................ ................................ ............................... 55 
Nonserious Adverse Events  ................................ ................................ ......................... 56 
6.7.1.  Assignment of Adverse Event Intensity and Relationship to 
Investigational Product  ................................ ................................ ................. 56 
6.7.2.  Collection and Reporting  ................................ ................................ .............. 57 
6.8. Reporting of Serious Adverse Events and Unanticipated Problems  ............................ 57 
6.8.1.  Investigator reporting:  notifying the IRB  ................................ .................... 58 
6.8.2.  Serious Adverse Events  ................................ ................................ ................ 58 
6.8.3.  Handling of Expedited Safety Reports  ................................ ......................... 60 
6.8.3.1.  Non-serious Adverse Events  ................................ .......................... 60 
6.9. Pregnancy  ................................ ................................ ................................ ..................... 61 
6.9.1.  Follow -up ................................ ................................ ................................ ......62 
6.10.  Immune -related Adverse Events  ................................ ................................ .................. 62 
6.11.  Rapid Notification of Adverse Events of Special Interest  ................................ ........... 63 
6.12.  Medical Monitoring  ................................ ................................ ................................ .....63 
6.12.1. Data and Safety Monitoring Committee  ................................ ....................... 64 
6.12.2.  Efficacy  ................................ ................................ ................................ ......... 64 
6.14  Other Safety Considerations  ................................ ................................ ........................... 64 
7. Data handling and record keeping  ................................ ................................ ....................... 64 
7.1. Confidentiality Regarding Study Subjects  ................................ ................................ ...64 
7.2. Confidentiality and HIPAA  ................................ ................................ ......................... 65 
7.3. Source Documentation  ................................ ................................ ................................ .65 
7.4. Data and Source Documentation  ................................ ................................ ................. 65 
7.5. Recording of Data and Retention of Documents  ................................ ......................... 66 
8. STUDY MONITORING, AUDITING AND INSPECTING  ................................ ............. 66 
8.1. Study Monitoring Plan  ................................ ................................ ................................ .66 
8.2. Auditing Procedure  ................................ ................................ ................................ ......68 
9. Ethical aspects  ................................ ................................ ................................ ........................ 68 
9.1. Ethic s and Good Clinical Practice  ................................ ................................ ............... 68 
10. Study Finances  ................................ ................................ ................................ ....................... 68 
10.1.  Funding Source  ................................ ................................ ................................ ............ 68 
10.2.  Subject Stipends or Payments  ................................ ................................ ...................... 68 
11. Publication plan  ................................ ................................ ................................ ..................... 68 
12. administrative requirements  ................................ ................................ ................................ .69 
Protocol S16 -00098  Confidential  Page 4 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 12.1.  Institutional Review Board  ................................ ................................ .......................... 69 
12.2.  Protocol Amendments  ................................ ................................ ................................ ..69 
13. REFERENCES  ................................ ................................ ................................ ....................... 70 
14. APPENDICES  ................................ ................................ ................................ ........................ 73 
Appendix 1:  Imaging Methodologies  ................................ ................................ .............. 74 
Appendix 2:  ECOG Performance Status  ................................ ................................ ........ 75 
Appendix 3:  Pre-existing Autoimmune Diseases  ................................ ........................... 76 
Appendix 4:  Description of Use of Blood Samples for Immune Analyses  ................... 77 
Protocol S16 -00098  Confidential  Page 5 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 SYNOPSIS  
TITLE  
A Pilot  Trial of Ipilimumab with NIVOLUMAB  for Patients with Resected Stages IIIB/ IIIC/ IV 
Melanoma  
PROTOCOL NUMBERS  
S16-00098  (Perlmutter  Cancer Center)  
CA209 -905(Bristol -Myers Squibb Co.)  
OBJECTIVES  
The primary objective of this study is to assess the safety and tolerability of tre atment with 
NIVOLUMAB  in combination with ipilimumab in HLA unrestricted subjects with resected Stages 
IIIB/ IIIC/IV melanoma.  
The secondary objectives of this study are to:  
 evaluate the immune response to treatment with the study drugs at Week 12  
 assess the preliminary efficacy of the study drugs as measured to time to relapse.  
OVERVIEW OF STUDY DESIGN  
This is a pilot, p hase II, open -label, single center study of NIVOLUMAB  in combination with 
ipilimumab. NIVOLUMAB  is an FDA -approved  fully human monoclonal  antibody (HuMAb) against 
programmed death -1 (PD -1). (See STUDY DRUGS, DOSES, AND ADMINISTRATION).  Ipilimumab 
is a FDA -approved fully human monoclonal antibody against cytotoxic T lymphocyte antigen -4 (CTLA -
4) 
The study will consist of 4  periods: Screenin g (up to 4 weeks), Induction Treatment (up to 1 12 -week 
cycle  of induction therapy with ipilimumab and NIVOLUMAB ), Treatment/Follow -up (up to 48 weeks of 
NIVOLUMAB ), and Survival Follow -up. Each induction treatment cycle is comprised of 4 doses of 
NIVOLUMA B and 4 doses of ipilimumab given every three weeks for a total of 12 weeks (cycle 1) with 
a tumor assessment at the end of cycle 1 at week 12.   
At the end of the Induction Treatment Period (Week 12 ) subjects without evidence of relapse 
radiologically and clinically will be able to continue to receive NIVOLUMAB  treatment 480mg every 4 
weeks for 48 weeks . Subjects who relapse at the disease evaluations at Weeks 12, 24 or later will not 
receive further treatment with NIVOLUMAB . 
Patients who experience a DLT to NIVOLUMAB  and ipilimumab during or after cycle 1 will not receive 
further treatment with NIVOLUMAB  and ipilimumab.  
Subjects who prematurely discontinue 1 or both study drugs will complete the rema ining study visits and 
associated evaluations (without dosing of 1 or both study drugs, as applicable) indefinitely until 
withdrawal of consent for follow -up or death.  
Dosing during cycle 1 will consist of: 3 mg/kg of NIVOLUMAB  + ipilimumab at 1 mg/kg  
Dosing during cycles 2 -5 will consi st of flat dose NIVOLUMAB at 480 mg   
Since the drugs will be given concurrently, it will not be possible to attribute dose -limiting toxicities to 
one or the other drug during the first 12 weeks of therapy.  
Subjects who withd raw from the study during Cycle 1 for reasons other than a DLT will be replaced.  
Protocol S16 -00098  Confidential  Page 6 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 No dose escalations or de -escalations are permitted within each subject’s treatment . NIVOLUMAB  or 
ipilimumab dose adjustments are allowed only if there has been  10% weight change since the previous 
treatment  (Induction/ Treatment Period  only).  No dose escalations or de -escalations are allowed during 
cycles 2 -5 due to the use of flat dosing of NIVOLUMAB at 480 mg every 4 weeks.  
NUMBER OF SUBJECTS (PLANNED)  
Up to 25 subjects (20 in this trial with five to account for drop -outs) will be enrolled in the study.  
BLINDING AND RANDOMIZATION  
This is an open -label study. Eligible subjects will be treated in the order they enter the study.  
DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION  
Subjects will have no HLA restriction, and have a histological diagnosis of Stages IIIB/ IIIC/IV 
Melanoma that has been completely resected, rendering them free of disease.   
STUDY DRUGS, DOSES AND MODE OF ADMINISTRATION  
NIVOLUMAB  will be supplied  as a sterile, preservative -free solution in 10  mL vials at a concentration of 
10 mg/mL; which, in cycle 1, based on the subject’s weight, may be diluted with sterile normal saline 
(0.9%  sodium chloride). NIVOLUMAB  (3 mg/kg) will be administered as a 30-minute i.v. infusion .    
Starting 4 weeks after the last co -administered dose in cycle 1, subjects will be administered a flat dose 
480 mg nivolumab IV every 4 weeks (Q4W) in cycles 2 -5.  
Ipilimumab will be supplied as a sterile, preservative -free solution i n 10mL (50 mg) or 40  mL (200 mg) 
vials at a concentration of 5  mg/mL; which, based on the subject’s weight, may be diluted with sterile 
normal saline (0.9%  sodium chloride). Ipilimumab ( 1 mg/kg ) will be administered as a 30-minute i.v. 
infusion.  
On days w hen both study drugs are administered, nivolumab ( BMS -936558) will be given before 
the ipilimumab.   
DURATION OF TREATMENT/STUDY PARTICIPATION  
The expected maximum duration of nivolumab treatment for a subject is 60 weeks . The expected 
maximum duration of ipilimumab treatment for a subject is 12 weeks.  
The expected maximum duration of a subject’s participation in this study is 3 years.  
CRITERIA FOR EVALUATION  
Safety  
Evaluation of safety and tolerability will include ongoing review of clinical laboratory tests (blood and 
urine sampling for clinical laboratory parameters), pregnancy testing, Eastern Cooperative Oncology 
Group (ECOG) performance status, physical examination including vital sign measurements, 
electrocardiogram (ECG), chest radiography, and ad verse events. Safety will also include evaluations of 
immune safety and immunogenicity.  
Dose -limiting Toxicity  
A DLT is defined as a NIVOLUMAB  and/or ipilimumab -related > Grade 3 adverse event occurring 
within 29 days after the first dose  of study drugs excluding: Grade 3 adverse event of tumor flare (defined 
Protocol S16 -00098  Confidential  Page 7 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 as local pain, irritation, or rash localized at sites of known or suspected tumor), Grade 3 rash, Grade 3 
immune -related adverse event (irAE, defined below) that resolves to a Grade 1 or less within 28  days, or a 
transient (resolving within 6  hours of onset) Grade 3 infusion -related adverse event. A Grade 3 irAE that 
resolves to a Grade 1 or less within 28 days, while not constituting a DLT, may preclude further 
administration of NIVOLUMAB  or NIVOLUMAB  with ipilimumab to the subject.  Grade 2 irAEs may 
require skipping a dose unless resolved to grade 1 or less at the time of drug administration. Version 4.0 
of the NCI Common Terminology Criteria for Adverse Events (CTCAE) will be utilized for AE 
reporting .  Version 4.0 of the CTCAE is identified and located on the CTEP website at 
http://c tep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .  All appropriate treatment 
areas should have access to a copy of Version 4.0 of CTCAE ). 
Toxicities occurring more than 28 days after the first dose will be monitored and discussed with BMS . 
Immune -Related Adverse Events  
An irAE is defined as a clinically significant adverse event of any organ that is associated with either 
study drug exposure, of unknown etiology, and is consistent with an immune -mediated mechanism. 
Appropriate efforts shou ld be made to rule out neoplastic, infectious, metabolic, toxin, or other etiologic 
causes of the irAE.  
Given the intended mechanism of action of NIVOLUMAB  and ipilimumab, particular attention will be 
given to adverse events that may follow enhanced T -cell activation such as dermatitis and colitis, or other 
irAEs.  
Immunology  
Blood and peripheral blood mononuclear cell samples will be collected and evaluated by leukapheresis or 
peripheral blood draw for flow cytometry (T cell, B cell, NK, monocytes, CD3, CD4 , CD8, CD4/CD8, 
CD11b, CD11c, CD14, CD20, CD25, CD33, CD56, CD69, CD71, CD73, CD80, CD127, FOXp3,  
LAG3, TIGIT, BTLA, Tim3, CTLA -4, PD -1, PD -L1, CD244, OX -40, 41 -BB, CD40, CD4/MHC Class II 
positive cells, and CD8/MHC Class II positive cells), serum cytokin es (IL -6, IL -10, TNF -β, ING-gamma, 
TGF -β, neopterin and sIL -2R), cellular immune function (tetramer and/or ELIspot assays utilizing 
melanoma and other control antigens).  
Serum samples will be collected and cryopreserved to study molecules that may be implicated in 
regulating anti -melanoma immune responses and/or NIVOLUMAB or ipi limumab activity such as 
soluble MICA , compounds detected by mass spectroscopy including those associated with wound 
healing, complement and the acute phase response, chemokines  or cytokines,  or antibodies to melanoma 
antigens.   
   
Efficacy  
Using imaging results (computed tomography/magnetic resonance imaging [chest, abdomen, pelvis, and 
brain] and photography of lesions) as well as clinical examination, presence of relapse will be evaluated 
and treatment decisions will be made by the Investigator (who is also the Sponsor). Scans  and 
measurements may be reviewed by independent radiologists at a later date or any time during the study.  
The primary efficacy endpoint is relapse free survival as determined by the results of Investigator 
evaluations.  
STATISTICAL METHODS  
A sample size of up to 20 subjects with 5 additional patients to accommodate drop -outs is based on the 
study design for safety evaluation requirements.  
Protocol S16 -00098  Confidential  Page 8 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 The incidence, r elationship to therapy, and severity of adverse events will be summarized using 
descriptive statistics. Changes in clinical laboratory tests, ECOG, vital signs, ECGs, chest radiography, 
and immune safety results will be summarized using descriptive statist ics. Immunogenicity results will be 
provided as a listing.  
Immune response will be summarized using descriptive statistics .. 
Efficacy evaluations  (RFS)  will be summarized using descriptive statistics.  
 
Protocol S16 -00098  Confidential  Page 9 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 ABBREVIATION  
Abbreviation  Term  
-HCG  beta human chorionic gonadotropin  
AIDS  acquired immunodeficiency syndrome  
ALT  alanine aminotransferase  
APC  antigen -presenting cells  
AST  
BMS  aspartate aminotransferase  
Bristol -Myers Squibb  
BOR  Best Overall Response  
BORR  Best Overall Response Rate  
CI 
CR confidence interval  
Complete Response  
CRF  case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
CTEP  Cancer Therapy Evaluation Program  
CTLA -4 cytotoxic T lymphocyte -associated antigen 4  
DC dendritic cells  
DLT  dose-limiting toxicity  
DNA  deoxyribosenucelic acid  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
ESI event of special interest  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GI Gastrointestinal  
HBV SAg  hepatitis B virus surface antigen  
HCV RNA  hepatitis C virus ribonucleic acid  
HIV human immunodeficiency virus  
HPF high power field  
HuMAb  human monoclonal antibody  
i.v. intravenous, intravenously  
ICF informed consent form  
ICH International Conference on Harmonisation  
IL-2 interleukin -2 
INF Interferon  
irAE  Immune -related adverse event  
IRB Institutional Review Board  
irCR  Immune -related complete response  
irPD  Immune -related progressive disease  
irPR Immune -related partial response  
Protocol S16 -00098  Confidential  Page 10 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Abbreviation  Term  
irRC  Immune -related Response Criteria  
irSD  Immune -related stable disease  
mAb  monoclonal antibody  
NIVOLUMAB  PD-1-specific, fully human IgG4 mAb  
MedDRA  Medical Dictionary for Regulatory Activities  
mWHO  
MPR  Modified World Health Organization  
Mixed Lymphocyte Reaction  
MTD  maximum tolerated dose  
NCI National Cancer Institute  
PBMC  
PCC  peripheral blood mononuclear cells  
Perlmutter Cancer Center  
PD-1 Programmed Death –1 
PD-L1 
PI 
PR Programmed Death –Ligand 1  
Propidium Iodide  
Partial Response  
PVG  Pharmacovigilance  
SAE  serious adverse event  
RECIST  Response Evaluation Criteria in Solid Tumors  
SOC  system/organ/class  
SOP standard operating procedure  
SPD Sum of Product Diameters  
SSAE  Serious or Significant Adverse Event  
TEAE  treatment -emergent adverse event  
TNF  tumor necrosis factor  
ULN  upper limit of normal  
URTI  upper respiratory tract infection  
US United States of America  
UTI urinary tract infection  
WBC  white blood cell  
WHO  World Health Organization  
 
Protocol S16 -00098  Confidential  Page 11 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 
 TABLE 1: TIME AND EVENTS SCHEDULE  
 
 Examination  Screening  Cycle 1 Treatment Period  11,13                                               
(Visits must occur ± 7 days of the 
scheduled visit)  Cycle 2 -5 Treatment Period11, 13                                                          
(Visits must occur ± 7 days of scheduled visit; 
Every 4 weeks for 48 weeks ) Study 
Completion/Early 
Withdrawal       
(Visit to occur 12 
week ± week after 
last dose)  Survival 
Follow -up 
Visit  1 2 3 4 5 6 7 8 9 10 11 12     
Week   -1 1 4 7 10 12           
Timepoint (Day)   -28 to -1 1 22 43 64 78       
Safety Procedures  
Vital Signs5 ● ● ● ● ● ● ● ● ● ● ● ● ●   
Height  ● ●       ●           ● ●   
Weight  ● ● ● ● ● ● ● ● ● ● ● ● ●   
Screening Procedures  
Informed Consent/ 
HIPAA9 ●                           
Inclusion/Exclusion 
criteria  ●                           
Demographics/ 
medical history  ●                           
Serum β -HCG 
pregnancy test  4 ●                           
Hepatitis B and C 
testing  ●                           
HIV testing  ●                           
Protocol S16 -00098  Confidential  Page 12 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 TABLE 1: TIME AND EVENTS SC HEDULE  
 
 Examination  Screening  Cycle 1 Treatment Period  11, 13                                               
(Visits must occur ± 7 days of the 
scheduled visit)  Cycle 2 -5 Treatment Period11, 13                                                        
(Visits must occur ± 7 days of scheduled visit; Every 
4 weeks for 48 weeks ) Study 
Completion/E
arly 
Withdrawal           
(Visit to occur 
12 week ± 
week after last 
dose)  Survival 
Follow -
up 
Visit  1 2 3 4 5 6 7 8 9 10 11 12     
Week  -1 1 4 7 10 12           
Timepoint (Day)  -28 to -1  1 22 43 64 78       
Safety Assessments  
Physical 
examination  ● ● ● ● ● ● ● ● ● ● ● ● ●   
ECOG performance  ● ● ● ● ● ● ● ● ● ● ● ● ●   
Electrocardiogram  6 ●                           
Chest radiograph  6 ●                           
Hematology  7 ● ● ● ● ● ● ● ● ● ● ● ● ●   
Serum chemistries  7 ● ● ● ● ● ● ● ● ● ● ● ● ●   
Urinalysis  ● ●     ● ●           ● ●   
Immune safety 
assays  7 ●        ●             ● ●   
Urine pregnancy 
test 4   ● ● ● ● ● ● ● ● ● ● ●     
Concomitant 
medications  ● ● ● ● ● ● ● ● ● ● ● ● ●   
Baseline medical 
history  ●                           
Adverse events  ● ● ● ● ● ● ● ● ● ● ● ● ●   
Protocol S16 -00098  Confidential  Page 13 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 TABLE 1: TIME AND EVENTS SC HEDULE  
Examination  Screening  Cycle 1 Treatment Period  11, 13                                                
(Visits must occur ± 7 days of the 
scheduled visit)  Cycle 2 -5 Treatment Period11, 13                                                        
(Visits must occur ± 7 days of scheduled visit; Every 
4 weeks for 48 weeks ) Study 
Completion/
Early 
Withdrawal           
(Visit to 
occur 12 
week ± week 
after last 
dose)  Survival 
Follow -
up 
Visit  1 2 3 4 5 6 7 8 9 10 11 12     
Week  -1  1 4 7 10 12           
Timepoint (Day)  -28 to -1  1 22 43 64 78       
Resea rch Procedures  
 Sample for 
immunogeni
city7 
 ●   ●        ●
1
3 
●  
 Serum for 
cytokine 
panel7 
  ●     ●              ●
1
3 
●   
 Cellular 
immune 
assays7 
  ●     ●              ●
1
3 
●   
 Cryopreserv
ed serum7 
  ●     ●              ●
1
3 
●   
 Tissue 
Submission1
4   ● ●15   ●15   ●15  ●15  ●15   ●15  ●15 ●15  ●15 ●
1
5  ●15 
Protocol S16 -00098  Confidential  Page 14 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Efficacy Procedures  
CT/MRI (neck, 
chest, abdomen, 
pelvis)  9, 12 ●          ●
1
4 
           ●
1
4 
● ● 
CT/MRI (Brain)  ●          ●
1
4 
           ●
1
4 
● ● 
Follow -up contact10                           ● 
Study Drug Administration  
Ipilimumab11   ● ● ● ●                   
Nivolumab  2,11   ● ● ● ● ●13 ● ● ● ● ● ●     
Key: CT = computed tomography, HIV = human immunodeficiency virus; ECOG = Eastern Cooperative  Oncology Group; MRI = magnetic resonance 
imaging   
FOOTNOTES:  
 
1Every effort should be made to infuse NIVOLUMAB in a 60 -minute timeframe.  
2 The NIVOLUMAB dosage may be adjusted if there is a  10% weight change since the previous weight measurement  only during cycle 1 
Induction Treatment.   No dose escalations or de -escalations are allowed during cycles 2 -5 due to the use of flat dosing of NIVOLUMAB at 480 
mg every 4 weeks.  No dose escalations o r de-escalations are allowed during cycles 2 -5 due to the use of flat dosing of NIVOLUMAB at 480 mg 
every 4 weeks.  
3 Informed consent must be signed before initiation of any study drug treatment or procedure. It may be signed more than 28 day s before the f irst 
dose.  
4 Pregnancy testing must be performed before any study drug is administered. The test result must be negative for a subject to receive study 
drug(s).  
5 Vital signs will be monitored immediately prior to the NIVOLUMAB infusion; every 15 minutes during the 30 or 60 -minute NIVOLUMAB 
infusion; and 15 and 30 minutes  after completion of the NIVOLUMAB infusion. When slowing or re -starting the NIVOLUMAB infusion due 
to an infusion reaction/adverse event, vital signs should be monitored every 15  minutes or as directed by the Investigator until the infusion is 
completed, and 15 and 30 minutes after completion of the infusion and/or the subject is stabilized.  
6 These evaluations are for baseline reference; subsequent evaluations may be performed if clinical ly indicated.  
Protocol S16 -00098  Confidential  Page 15 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 7 Sample to be drawn/collected pre -treatment at visits where 1 or more study drug will be administered. Hematology and serum chemistries for 
Cycle 1 Day 1 will not be re -drawn if screening labs were completed within 72 hours prior to study dr ug administration. This treatment group 
will draw amylase and lipase  also. 
8 CT neck will be done only in patients wit h prior disease in the head and neck 
9 In patients who have not had disease progression, re -imaging should be performed every 6 -12 months (minimum of every 12 months) for the first 
2 years, then every 12 months (at the discretion of the treating physician) indefinitely or until progression.  
10 Survival statuses for all patients who have discontinued from study treatment will be collected every 6 months (+/ - 1 month) until death, lost to 
follow -up, or withdrawal of consent for survival follow -up. Follow -up contact may be done in person at the st udy center or by telephone; 
survival information may be obtained from family members or other medical professionals caring for the patient. Survival info rmation including 
post-study treatment modalities and date and site of disease progression will be docu mented in the source documents and survival eCRF. Social 
security death index (SSDI) and other public records will be used if necessary to confirm survival status and/or date of deat h. 
11  There is only one 12 week induction treatment cycle  (cycle 1) . The ipilimumab will be at 1 mg/kg every 3 weeks for 4 doses during the 12 week 
induction cycle , and NIVOLUMAB  will be at 3 mg/kg every 3 weeks for 4 doses during the 12 week induction treatment cycle  then at 480mg  
every 4 weeks for 48 weeks during cycles 2 -5. 
12 To be obtained every 12 weeks.  Patients that discontinue therapy for any reason will only have the immunology procedures collected at the next 
mandated protocol timepoint, but not thereafter.   
13 Radiology exams will be completed prior to dosing at we ek 12 and every 12 week s prior to each dosing visit.   
14 Tissue will be submitted, if available, as outlined in section 5.6.1  
15 Tissue from any post -relapse biopsy will be requested for analysis by immunohistochemistry as outlined in section 5.6.1.  
 
Protocol S16 -00098  Confidential  Page 16 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 
 1. INTRODUCTION AND RAT IONALE  
1.1. Disease Description  
In the United States, it is estimated that in 20 16, approximately 84,000  patients were  diagnosed with 
malignant melanoma, and that there were  an estimated 9,200  deaths from melanoma.1 Melanoma is the 
most serious form of skin cancer and strikes adults of all ages. The male to female incidence ratio of 
melanoma is 1.3:1, respectively. Melanoma is primarily a disease of whites; rates are more than 10  times 
higher in  whites than in African Americans. Melanoma incidence rates have been increasing for at least 
30 years. In the most recent time period, rapid increases have occurred among young white females (3.8% 
annual increase since 1995 in those aged 15 to 34 years) a nd older white men (8.8% annual increase since 
2003 in those 65 and older).   
Treatment for melanoma includes removal of the primary growth and surrounding normal tissue and 
sentinel lymph node biopsy to determine stage. More extensive lymph node surgery ma y be done if 
lymph node metastases are present. Melanomas with deep invasion or that have spread to lymph nodes 
may be treated with immunotherapy, radiation therapy, and/or surgery and chemotherapy. Advanced 
cases of melanoma are treated with palliative su rgery, immunotherapy, and/or chemotherapy, and 
sometimes radiation therapy.  
Melanoma is more likely than other skin tumors to spread to other parts of the body. The 5 - and 10 -year 
relative survival rates for persons with melanoma are 91% and 90%, respecti vely. For localized 
melanoma, the 5 -year survival rate is 99%; 5 -year survival rates for regional and distant stage diseases are 
65% and 16%, respectively. About 80% of melanomas are diagnosed at a localized stage. 1 
1.2. Principles of the Proposed Therapies  
The importance of the immune system for controlling the emergence and progression of cancer, 
historically a question of heated debate, is now widely accepted. Advances in immunology and oncology 
have revealed a chronic and dynamic interplay between host and tumor, suggesting that the ability of the 
tumor to evade the immune response often determines the clinical course of the disease.2 Enhancement of 
the magnitude and potency of tumor antigen -specific adaptive cellular responses by CD8 and CD4 T cells 
is a major goal in cancer immunotherapy.  
T-cell activity is controlled by antigen -specific stimuli sensed by the T -cell receptor and by the combined 
activ ity of both positive (costimulatory) and negative (coinhibitory) T -cell surface molecules. Inhibition 
of these negative regulatory receptors, referred to as checkpoint blockade, results in the enhanced 
activation of T -cell responses and potent antitumor ac tivity in preclinical models. One of the most 
extensively studied negative regulatory receptors is programmed death -1 (PD -1 [CD279]). Advances in 
the understanding of mechanisms that regulate T -cell activation have allowed the rational design of new 
strate gies for immunotherapy of tumors, including melanoma. A monoclonal antibody recognizing PD -1 
(NIVOLUMAB ) is an immunotherapy currently  approved for melanoma, non -small cell lung cancer, 
renal cell cancer and non -Hidgkins lymphoma, and is  in development as an anticancer agent  for multiple 
Protocol S16 -00098  Confidential  Page 17 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 other indications . The proposed mechanism of action of NIVOLUMAB  is interference of the interaction 
of PD -1 with its ligands PD -L1 (CD274) and PD -L2 (CD273). Preclinical and clinical data indicate that 
NIVOLUMAB  has antican cer activity.  
Major limitations of recent cancer vaccine strategies have been that low levels of poorly reactive T cells 
are generated due to counter -regulatory signals, tolerance to self tumor antigens limits the avidity of 
resulting T cells, and high le vels of T regulatory cells are observed in cancer patients. The ability to 
vaccinate cancer patients may be improved not only by increasing the total quantity of induced T cells, 
but by also increasing their recognition efficiency (RE) or avidity for cogna te peptide presented by tumor 
cells.  It has been suggested that modulation of costimulatory signals in vaccinated mice can selectively 
induce high avidity T cells that are specific for self and non -self antigens.3,4. We hypothesize that PD -1 
blockade  comb ined with CTLA -4 blockade using ipilimumab  would have a favorable effect on the 
expansion and activity of human CD8+ T cytotoxic lymphocytes (CTLs) specific for tumor -associated 
antigens (ie, self antigens), which would translate into improved anti -cancer therapy.  
1.2.1.  NIVOLUMAB  
The PD -1 receptor is predominantly expressed on activated T and B lymphocytes, as well as memory T 
lymphocytes.5,6,7,8 The interaction of PD -1 with its ligands, PD -L1 and PD -L2, which are expressed on 
APC and dendritic cells (DC), transmits negative regulatory stimuli to down modulate the activated T -cell 
immune response. Loss of effective immune response to antigens expr essed by tumors may be a 
significant factor in tumor progression. PD -L1 expression has also been found on a number of tumors and 
may be a mechanism by which tumors can directly engage PD -1 to evade an effective antitumor immune 
response. PD -1 engagement on  T cells by PD -L1+ APC or PD -L1+ tumor cells in the tumor 
microenvironment and the tumor -draining lymph nodes may prematurely limit effective immune 
responses. High PD -1 expression on antigen -specific T cells, as a consequence of chronic antigenic 
stimulat ion, is thought to be a marker of T -cell exhaustion or anergy. Antibody -mediated blockade of the 
interaction of PD -1 with its main ligand, PD -L1, can lead to the reversal of antigen specific anergy .  
Protocol S16 -00098  Confidential  Page 18 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 1.2.2.  Ipilimumab  
The CTLA -4 recep tor is predominantly expressed on activa ted T effector cells and regula tory T cells. It 
binds its ligands CD80 and D86 on dendritic cells and antigen presenting cells and mediates a signal that 
like PD -1 down modiulated T cell proliferation and activation. Its action is mostly  at the immune priming 
phase in the lymph nodes, and differs from PD -1 in that it acts not at the tumor microenvironment but in 
lymphoid tissue earlier in the immune response. Its abrogation with a human IgG1 antibody has been 
associated with clinical bene fit in phase III studies but also a high degree of immune related adverse 
events9-12.  Its use as an adjuvant has been shown in stage III melanoma to prolong relapse -free survival, 
and recently published data suggest that it prolongs overall survival in st age III resected melanoma with a 
hazard ratio of 0.72, establishing a rationakle for its use in an adjuvant strategy in combination with 
NIVOLUAMB13-14. 
1.3. Preclinical Summary of NIVOLUMAB  
NIVOLUMAB  has been shown to bind specifically to the PD -1 receptor of the CD28 family. In vitro 
assays have demonstrated that NIVOLUMAB  does not react with the other members of this family. 
NIVOLUMAB  has also demonstrated the ability to block binding of its ligands, PD -L1 and PD -L2, and 
to enhance T -cell proliferation and IF N-γ release in vitro. A surrogate anti -murine PD -1 antibody was 
effective in inhibiting tumor growth in several syngeneic tumor models.  
In binding studies using fresh, frozen human tissues, NIVOLUMAB  demonstrated reactivity with 
lymphocytes in a variety of  tissues. There was also moderate to strong cytoplasmic staining of rare to 
occasional endocrine cells in the adenohypophysis. This was considered to be low affinity binding as the 
intensity was moderate to strong at 10 µg/mL and was not present at 1 µg/mL . This unexpected reactivity 
to endocrine cells is not expected to have physiological consequences due to the limited availability of 
cytoplasmic compartments in vivo. Similar staining patterns were observed in cynomolgus monkey 
tissues indicating that thi s is an appropriate animal species to evaluate the potential toxicities of 
NIVOLUMAB . In a cardiovascular, safety pharmacology study in cynomolgus monkeys, there were no 
significant effects of administration of 10 or 50 mg/kg of NIVOLUMAB  on electrocardiog raphic 
parameters. NIVOLUMAB  was also well tolerated when administered weekly at doses of 1, 10 or 50 
mg/kg/dose for 5 weeks and when administered bi -weekly at doses of 10 and 50 mg/kg for 3 months. 
There were no adverse clinical findings or changes in cli nical or anatomic pathology parameters in these 
studies.  
In a study of cynomolgus monkeys which were administered multiple doses of ipilimumab, a fully human 
mAb to CTLA -4, in combination with NIVOLUMAB , 1 monkey at the highest dose level (10 mg/kg 
ipilim umab/50 mg/kg NIVOLUMAB ) died 1 day following the fourth and last doses of ipilimumab and 
NIVOLUMAB , respectively. This early death was attributed to acute gastric dilation, assessed as possibly 
related to administration of ipilimumab plus NIVOLUMAB . Clinical observations in the days before 
death included persistent diarrhea, reduced food consumption, weight loss, decreased activity, 
dehydration, and hypothermia. Pathology findings included marked gas distention of the stomach and 
Protocol S16 -00098  Confidential  Page 19 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 moderate gas dilata tion of the duodenum, jejunum, ileum, cecum, and colon (correlated with decreased 
thickness of the gastric and intestinal wall, submucosal and muscularis), mottled, dark red, purple, tan 
discoloration of the lung (correlated with vascular congestion and a pulmonary granuloma), abnormal 
appearance of the lung due to atelectasis and hyperinflation (no microscopic correlate), decreased thymus 
size (correlated with marked, diffuse thymic atrophy), and purple discoloration of the neck and thorax (no 
microscopic correlate). One microscopic finding of uncertain relationship to ipilimumab plus 
NIVOLUMAB  administration was identified in the kidney: mild multifocal tubular dilation and epithelial 
degeneration in the renal cortical  tubules. Myeloid and eosinophil hyper cellularity and erythroid 
hypocellurity were identified in the bone marrow. Myeloid and eosinophil hypercellularity were believed 
to be a secondary response to inflammation in the lung and not related to ipilimumab/ NIVOLUMAB  
treatment. The cause of the ery throid hypocellularity was considered uncertain. Additional microscopic 
findings considered to be related to inappetence or physiological stress and not test article treatment 
included thymic involution/atrophy, pancreatic acinar cell degranulation, secret ory depletion of the 
adrenal cortex, zona fasciculate and vascular congestion in several organs examined. All other gross 
observations or microscopic findings were considered incidental. There was no evidence of colitis upon 
gross or microscopic pathology evaluation of the gastrointestinal tract. The animal did develop diarrhea 
and this occurred in the cohort receiving the highest doses of the test articles. Therefore, the death may 
possibly be related to administration of ipilimumab and NIVOLUMAB  and may b e an immune -mediated 
gastrointestinal toxicity.  
In addition to the case described above, there was an increased incidence of persistent diarrhea in the 
high-dose animals in this study (5 of 10 animals affected vs 0 of 10 control animals) and an incidence o f 
diarrhea in 1 of 10 low -dose animals.  
1.4. Clinical Summary  
Prior clinical studies have been conducted with NIVOLUMAB  in combination with a peptide vaccine. In 
this clinical study we will administer NIVOLUMAB  in combination with IPILIMUMAB  for resected 
melan oma.  
There are currently no open adjuvant trials for children 16 -21 years of age with resected high risk 
melanoma. In prior adjuvant trials conducted by the investigator at Moffitt Cancer Center, such patients 
ages 16 -21 have been routinely included.  Tha t population is also treated in the community with adjuvant 
high dose interferon alpha, which has minimal efficacy in overall survival.  In a recently published study, 
33 pediatric patients under 21 were treated with ipilimumab immunotherapy ( Merchant MS, Wright M, 
Baird K, Wexler LH, Rodriguez -Galindo C, Bernstein D, Delbrook C, Lodish M, Bishop R, Wolchok JD, 
Streicher H, Mackall CL.  Phase I Clinical Trial of Ipilimumab  in Pediatric  Patients wi th Advanced Solid 
Tumors.   Clin Cancer Res. 2016 Mar 15;22(6):1364 -70. doi: 10.1158/1078 -0432.CCR -15-0491. Epub 
2015 Nov 3.  PMID: 26534966) demonstrating that the toxicity was quite similar to that seen in adult 
patients over 21.  There is no reason to po stulate that the side effects of nivolumab would be any different 
in the 16 -21 population than in an older cohort of resected melanoma patients. The only other alternative 
for these patients would be off -protocol ipilimumab adjuvant therapy at the FDA appr oved 10 mg/kg 
dose, which has a 41% rate of grades 3 -4 toxicity, regarded by many as a very toxic regimen13.  
Therefore, given the prior safe experience of the investigator with the age 16 -21 population being treated 
Protocol S16 -00098  Confidential  Page 20 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 on immunotherapy adjuvant melanoma tria ls, the safety of ipilumumab alone documented in the literature 
in this cohort, the lack of effective or non -toxic alternative therapy available, it is felt that it is appropriate 
to include the age 16 -21 population in the current trial.  
 
1.4.1.  NIVOLUMAB  
Three Phase 1, dose -escalating clinical studies (at dose levels ranging from 0.01  mg/kg to 10  mg/kg) have 
been initiated with NIVOLUMAB : 2 in oncology (MDX1106 -01 and MDX1106 -03 [Phase 1b]) and 1 in 
hepatitis (MDX1106 -02)15. Data entered into the NIVOLUMAB  database as of 28 May 2009  show that 
76 subjects have received 1 or more doses of NIVOLUMAB  (25 at the highest 10  mg/kg dose level). In 
these studies, there was no pattern in the incidence, severity, or relationship of adverse events to 
NIVOLUMAB  dose lev el. The main toxicities noted include fatigue, anemia, increase in blood alkaline 
phosphatase, decrease in weight, and lymphopenia. No dose -limiting toxicities have been observed, and 
only 1 subject (1 mg/kg) experienced a serious adverse event considered to be related to NIVOLUMAB  
(colitis). There were no study drug -related deaths.  
Preliminary efficacy results for the 2 cancer studies showed sustained responses to NIVOLUMAB  in 
3 subjects, 1 each in the 1 mg/kg (renal carcinoma), 3 mg/kg (colorectal cancer) , and 10  mg/kg (renal 
carcinoma) dose cohorts. The times to response (and durations of response) were 56  days (57 + days), 
57 days (530 + days), and 85 (295 + days) for the 1  mg/kg, 3 mg/kg, and 10  mg/kg dose subjects, 
respectively. A fourth subject with m elanoma has been stable for 14+ months, and is still receiving 
NIVOLUMAB  10 mg/kg. Preliminary efficacy results from the single -dose hepatitis C study showed a 
transient response in 1 subject in the 0.1 mg/kg dose cohort (  0.5-log or greater decrease from  the 
baseline viral load, repeated on  2 consecutive measures) that was not clinically meaningful. CA209037 
was a multicenter, open -label study that randomized (2:1) patients with unresectable or metastatic 
melanoma to receive either nivolumab administere d intravenously at 3 mg/kg every 2weeks or 
investigator’s choice of chemotherapy (ICC), either single -agent dacarbazine 1000 mg/m2 every 3 weeks 
or the combination of carboplatin AUC 6 every 3 weeks plus paclitaxel 175 mg/m2 every 3 weeks. The 
efficacy res ults indictaed that responses were significantly higher in the NIVOLUMAB arm than the 
investigator choice arms, 32% versus 11%, leading to the FDA and EMA approvals of NIVOLUMAB in 
201414-19. Further randomized trials indicated the superiority of NIVOLUMAB  as treatment for metastatic 
disease.  
Due to the moderate  level of clinical experience with NIVOLUMAB , all expected toxicities have not 
been fully defined.  
1.4.2.  Rationale for the Original NIVOLUMAB  + Peptide Vaccine Clinical Study  
Clinical data indicate d a potential for treatment with NIVOLUMAB  in combination with a peptide 
vaccine to augment the T -cell immune response against specific melanoma antigens and result in 
antitumor effects that might prolong time to relapse in patients at very high risk of rec urrence.  The 
Protocol S16 -00098  Confidential  Page 21 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 previous experience did not justfy the inclusion of a peptide vaccine in the current cohort of patients with 
resected melanoma, so the current cohort includes patients treated with NIVOLUMAB + ipilimumab.  
 
1.4.3     Rationale for the NIVOLUMAB  + ipilimumab  clinical study   
As of the 15 -Feb-2013 clinical cut -off in trial CA209004 , in which patients received the combination of 
ipilimumab with NIVOLUMAB  concurrently or sequentially , of the 52 subjects evaluable for response, 
21 subjects (40%) had a n objective response by modified World Health Organization (mWHO) criteria20-
21. In an additional 2 subjects (4%) there was an unconfirmed objective response. In Cohort 1 (0.1 mg/kg 
nivolumab + 3 mg/kg ipilimumab), 3 out of 14 evaluable subjects had an obj ective response by mWHO 
(21%); 1 CR and 2 PRs with an additional PR by immune -related mWHO criteria (irPR). 55 In Cohort 2 
(1 mg/kg nivolumab + 3 mg/kg ipilimumab), 9 out of 17 evaluable subjects had an objective response by 
mWHO (53%; 3 CRs (18%), 6 PRs (35%) with two additional subjects experiencing immune -related SD 
(irSD). In Cohort 2a (3 mg/kg nivolumab +1 mg/kg ipilimumab), 6 out of 15 response evaluable subjects 
had an objective response rate by mWHO (40%; 1 CR (7%), 5 PRs (33%) wit h 2 additional uPRs (13%) 
and 2 irSDs and 1 irPR). In Cohort 3 (3 mg/kg nivolumab + 3 mg/kg ipilimumab), 3 out of 6 evaluable 
subjects had an objective response by mWHO (50%; 3 PRs (50%) with 1 additional irPR and 1 irSD. 
Preliminary analysis revealed 16 o f the 52 evaluable subjects (31%) had > 80% reduction in the size of 
target tumor lesions by the week 12 evaluation. This is compared to < 2% for 3 mg/kg ipilimumab 
monotherapy based on CA184020 (N=540) and < 3% for nivolumab monotherapy based on CA209003 
(N=94, 0.1 -10 mg/kg . Follow -up phase II data in the randomized CA209 -069 study of nivolumab + 
ipilimumab versus ipilimumab alone showed a 61% response rate and a 55% rate of grades 3 -4 irAEs for 
the combination at the nivolumab dose of 1 mg/kg and ipilimum ab at 3 mg/kg in the induction portion of 
the trial over the first 12 weeks.  These data led to the FDA approval of the combination regimen for 
unresectable melanoma in 201520-21. The most common (reported at > 10% incidence) treatment related 
AEs with the  combonation  are fatigue, rash, pruritus, diarrhea, lipase increased, pyrexia, ALT increase, 
AST increased, amylase increased and vitiligo. Although the preliminary data suggests an increase in 
adverse event frequency of nivolumab combined with ipilimumab compared to ipilimumab monotherapy 
or nivolumab monoth erapy, there were no unexpected adverse events noted in the combination of 
nivolumab and ipilimumab. In addition, many of the Grade 3 -4 adverse events associated with the 
nivolumab combined with ipilimu mab were laboratory i n nature, without clinical seque lae and adverse 
events have been manageable and reversible following intervention dose delays or with systemic steroid 
treatment. While the grade 3 irAE rate in that trial was 53%, the regimen was felt t o be well tolerated, 
with a high level of clinical activity.  The choice of the combination of NIVOLUMAB  and ipilimumab at 
the chosen doses  for cohort 4  of the predecessor trial MCC 15651 at Moffitt Cancer Center  was based on 
Protocol S16 -00098  Confidential  Page 22 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 the results of that study.22   In the experience of 20 patients treated in cohort 4, 10 have had toxicity that 
precluded finishing 12 weeks of therapy, suggesting that for patients with resected stages 3C and 4 
melanoma, the regimen of ipilimumab at 3 mg/kg and NIVOLUMAB  at 1 mg/kg every 3 weeks for 4 
doses may be difficult to tolerate, and suggesting that an alternative regimen of ipilimumab at 1 mg/kg 
and NIVOLUMAB  at 3 mg/kg every 3 weeks for 4 doses was wort hy of testing in  cohort 5  at Moffitt .  In 
that experience, 17  of the 20 patients treated were able to continue past the 12 -week combination period. 
In that cohort, treatment was for 2 years with nivolumab alone after the 12 -week induction with 
nivolumab and ipilimumab23. In the current protocol, an additional  20 pat ients will be treated with the 
same doses as cohort 5 at Moffitt (ipilimumab 1/nivolumab 3) and the total duration of nivolumab 
treatment alone will be 1 year, in order to gather further feasibility and toxicity experience with this 
adjuvant regimen.  
 
1.4.4 Rationale for evaluation of PD -L1 Expression as a Predictive Biomarker  
 
PD-L1 is expressed by many tumor types and its expression has been noted to correlate with decreased 
immune system function and worse clinical prognosis. It is hypothesized that PD -L1 expression within 
the tumor microenvironment, either on tumor cells, macrophages or lymphocytes is a means of evading 
immune system detection and destruction. Still others postulate that PD -L1 expression on tumor cells is a 
surrogate for interferon -gamma  release from neighboring activated T cells and thus portends a good 
prognosis for immunotherapy agents, and in particular, agents targeting the PD -1/PD -L1 axis. Preliminary 
data from two small retrospective analyses supports the latter hypothesis in metas tatic melanoma. PD -L1 
positive status was associated with improved OS, irrespective of treatment, relative to PD -L1 negative  
status in subjects with metastatic melanom a (n=56). Similarly, objective responses to nivolumab were 
limited to subjects defined as  PD-L1 positive in a subset of subjects from study CA209003 (n = 42), 
which included 18 melanoma subjects. In both of these studies, a prototype immunohistochemistry (IHC) 
assay was used and PD -L1 positive status was defined as > 5% tumor cell membrane sta ining within a 
tumor tissue sample. Based on these initial data, BMS  is in the process of developing a reproducible 
diagnostic IHC assay that can be used to measure PD -L1 expression in t umor tissue. Using the verified 
version of the diagnostic assay, BMS  has assessed additional tumor biopsy specimens from 38 CA209003 
melanoma subjects for PD -L1 expression. Using a cutoff of 5% tumor cell membrane staining, 45% of 
subjects were defined as PD -L1 positive, consistent with the rate previously reported by Taub e et al (STM 
2012) at 45% (24/56 subjects) in metastatic melanoma. With this verified version of the assay, an ORR of 
44% (7/16) was observed in subjects with > 5% tumor -cell positivity and 17% (3/18) in subjects with < 5 
% tumor cell positivity. The limit ed preliminary evidence suggests that PD -L1 expression may be a 
prognostic marker that may also predict for nivolumab clinical activity. Therefore, we will obtain pre -
Protocol S16 -00098  Confidential  Page 23 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 treatment FFPE tissue from all patients in the current trial, and perform IHC staining fo r PD-L1 at BMS 
to derive preliminary data whether tumor PD -L1 expression is associated with outcome in patients 
receiving NIVOLUMAB  or combined ipilimumab + NIVOLUMAB  as adjuvant therapy.  
1.4.5  Rationale for  Flat Dosing of NIVOLUMAB  
Nivolumab monotherapy  has been extensively studied in a number of tumor types including non -small 
cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), and colorectal cancer (CRC) with 
body weight normalized dosing (mg/kg). Nivolumab pharmacokinetics (PK) and exposur es of subjects in 
these studies have been characterized by population pharmacokinetic (PPK) analysis of data collected in 
these studies, together with PK data from several Phase 1, 2, and 3 clinical studies of nivolumab 
monotherapy in solid tumors. PPK ana lyses have shown that the PK of nivolumab are linear, with dose 
proportional exposures over a dose range of 0.1 mg/kg to 10 mg/kg, and are similar across tumor types. 
Nivolumab clearance and volume of distribution were found to increase with increasing bod y weight, but 
the increase was less than proportional, indicating that a mg/kg dose represents an over -adjustment for the 
effect of body weight on nivolumab PK. Given the relationship between nivolumab PK and body weight, 
a flat dose is expected to lead to  lower exposures in heavier patients, relative to the exposures in lighter 
patients.  
Using the PPK model, nivolumab steady -state trough, peak and time -averaged concentration (Cminss, 
Cmaxss, and Cavgss, respectively) were predicted for a flat nivolumab do se of 240 mg Q2W and 
compared to those following administration of 3 mg/kg Q2W in NSCLC, melanoma, and RCC subjects. 
A dose of 240 mg nivolumab is identical to a dose of 3 mg/kg for subjects weighing ~ 80 kg, which is the 
approximate median body weight of subjects in the Phase 2 and 3 BMS clinical studies of nivolumab 
monotherapy. From the simulations, the geometric mean values of Cminss, Cmaxss, and Cavgss with flat 
dosing are slightly (< 15%) higher than that produced by a 3 mg/kg dose, and the coefficien t of variation 
(cv%) in these measures of exposure are only slightly (< 10%) greater than that of 3 mg/kg dosing. Given 
the similarity of nivolumab PK across tumor types and the similar exposures predicted following 
administration of a 240 mg flat dose com pared to 3 mg/kg, it is expected that the safety and efficacy 
profile of nivolumab following a flat dose will be similar to that of 3 mg/kg nivolumab dose.  
Across the various tumor types in the BMS clinical program, nivolumab has been shown to be safe and  
well tolerated up to a dose level of 10 mg/kg, and the relationship between nivolumab exposure produced 
by 3 mg/kg and efficacy has been found to be relatively flat. Taken together, the PK, safety, and efficacy 
data indicate that the safety and efficacy p rofile of flat nivolumab dose every 2 weeks will be similar to 
that of a 3 mg/kg nivolumab every 2 weeks. In this study after completion of the combination portion of 
the study, all subjects will receive flat dose 480 mg nivolumab every 4 weeks (Q4W), whic h provides a 
more convenient dosing regimen for subjects. Based on PK modeling and simulations, administration of 
Protocol S16 -00098  Confidential  Page 24 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 nivolumab 480 mg Q4W will be started after steady state is achieved with the combination regimen. 
While 480 mg Q4W is predicted to provide gre ater (approximately 20%) maximum steady state 
concentrations and lower (approximately 10%) steady state trough concentrations, these exposures are 
predicted to be within the exposure ranges observed at doses up to 10 mg/kg Q2W used in the Phase 1 
nivolumab  clinical program, and are not considered to put subjects at increased risk. Similar to the 
nivolumab Q2W dosing monotherapy regimen, the exposures predicted following administration of 
nivolumab 480 mg Q4W, are on the flat part of the exposure -response cu rves for previously investigated 
tumors, melanoma and NSCLC, and are not predicted to affect efficacy. Based on these data, nivolumab 
480 mg Q4W is expected to have similar efficacy and safety profiles to nivolumab 3 mg/kg Q2W.  
Hence, doubling the dose of  nivolumab from 240 mg to 480 mg would extend the dosing interval from 2 
weeks to 4 weeks. Thus a flat dose of 480 mg every 4 weeks is recommended for investigation in the 
maintenance phase of this study during cycles 2 -5.  
STUDY OBJECTIVES  
1.5. Primary Objecti ve 
The primary objective of this study is to assess the safety and tolerability of treatment with 
NIVOLUMAB  in combination  with ipilimumab in subjects with resected Stages IIIB/ IIIC/  IV melanoma.  
1.6. Secondary Objectives  
The secondary objectives of this study are to:  
 evaluate the immune response to treatment with the study drugs at Week 12 . 
 assess the preliminary efficacy of the study drugs as defined by an assessment of time to relapse  
2. OVERVIEW OF STUDY DE SIGN  
2.1. General Design and Study Schema  
This is a pilot, p hase II, open -label, single center, multi -dose, study of NIVOLUMAB in combination 
with ipilimumab. NIVOLUMAB is an FDA -approved fully human monoclonal antibody (HuMAb) 
against programmed death -1 (PD -1). (See STUDY DRUGS, DOSES, AND ADMINISTRATION).  
Ipilim umab is a FDA -approved fully human monoclonal antibody against cytotoxic T lymphocyte 
antigen -4 (CTLA -4) 
The study will consist of 4  periods: Screening (up to 4 weeks), Treatment (up to 1 12 -week cycle), 
Treatment/Follow -up (up to 1 year), and Survival Fol low-up. Each treatment cycle is comprised of 4 
doses of NIVOLUMAB and 4 doses of ipilimumab given every three weeks for a total of 12 weeks (cycle 
1) with a tumor assessment at the end of cycle 1 at week 12.   
At the end of the Treatment Period (Week 12) subjects without evidence of relapse radiologically and 
clinically will be able to continue to receive NIVOLUMAB with flat dosing at 480mg every 4 weeks for 
48 additional weeks . Subjects who relapse at the disea se evaluations at Weeks 12, 24 or later will not 
receive further treatment with NIVOLUMAB.  
Protocol S16 -00098  Confidential  Page 25 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Patients who experience a DLT to NIVOLUMAB and ipilimumab during or after cycle 1 will not receive 
further treatment with NIVOLUMAB and ipilimumab.  
Subjects who pre maturely discontinue 1 or both study drugs will complete the remaining study visits and 
associated evaluations (without dosing of 1 or both study drugs, as applicable) indefinitely until 
withdrawal of consent for follow -up or death.  
Dosing in cycle 1 will consist of : 3 mg/kg of NIVOLUMAB + ipilimumab at 1 mg/kg  
Since the drugs will be given concurrently, it will not be possible to attribute dose -limiting toxicities to 
one or the other drug during the first 12 weeks of therapy.  
Subjects who withdraw from t he study during Cycle 1 for reasons other than a DLT will be replaced.  
No dose escalations or de -escalations are permitted within each subject’s treatment. NIVOLUMAB or 
ipilimumab dose adjustments are allowed only if there has been  10% weight change sin ce the previous 
treatment  (Induction Treatment Period  only). No dose escalations or de -escalations are allowed during 
cycles 2 -5 due to the use of flat dosing of NIVOLUMAB at 480 mg every 4 weeks.  
 
2.2. Primary Endpoint  
The primary efficacy analysis is time t o relapse . Time to relapse will be summarized using descriptive 
statistics. Scanning and exams to detect recurrence will be conducted every 3 months until 2 years from 
finishing treatment , then every 6 -12 months (minimum of every 12 months) for 2 years, th en yearly 
thereafter.  
2.3. Secondary Endpoint  
Overall survival will be the secondary efficacy endpoint; patients will be followed for survival 
indefinitely as indicated in the study schema.  
2.4. Benefit/risk ethical assessment  
2.4.1 Benefit  
The potential benefits to subjects with study participation are improved overall survival.  The information 
obtained from this research may help others with this disease in the future.  
2.4.2 Potential Risks of Study drug s 
NIVOLUMAB  and Ipilimumab  
In the Phase 1 MDX1106 -01 (singl e dose [with possible retreatment] cancer) study a single instance of an 
inflammatory colitis serious irAE has been reported. This event occurred after the subject received 5 
doses of 1 mg/kg NIVOLUMAB administered over 8 months and approximately 8 weeks a fter the last 
dose was administered. Twenty -one subjects have safely received at least 1  dose of 10  mg/kg, 6 received 
2 or more 10 mg/kg doses, including 1 subject who has received 9  (10 mg/kg) doses over 18 months. Low 
grade irAEs have included arthropath ies and declines in thyroid -stimulating hormone. Administration of 
NIVOLUMAB in the ongoing MDX1106 -02 (single  dose hepatitis) and MDX1106 -03 (multiple dose 
cancer) studies has been well tolerated to date.  In the current BMS CA209007 adjuvant study, no DL Ts 
Protocol S16 -00098  Confidential  Page 26 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 have been observed during the 29 day DLT period, but two episodes of grade 3 colitis have been observed 
after week 12, causing treatment with vaccine plus NIVOLUMAB to be discontinued.  Both patients 
recovered fully with prolonged steroid tapers and are  currently free of disease more than a year after the 
episode(s) of colitis.  
Other possible toxicities with NIVOLUMAB, and ipilimumab may be anticipated based on general 
experience with other mAbs, preclinical data, and clinical studies with similar inves tigational agents. 
Possible toxicities could affect the immune system, hematologic, cardiovascular, hepatic, 
musculoskeletal, and other systems, and may include:  
 Infusion reactions: Fever, chills, shakes, itching, rash, hyper - or hypotension, difficulty br eathing. 
It is likely that most infusion -related adverse events will occur within the first 24  hours after 
beginning the infusion, and may be treated by slowing or interruption of the infusion, or with 
supportive treatment as indicated in S ection 5.2.2 . 
 Widespread immune activation/cytokine storm:  Cytokine storm adverse events may initially 
look like allergic reaction/hypersensitivity, but are distinguished by more sustained and profound 
hemodynamic disturbances related to the widespread release of cytokine s such as IL -1 and tumor 
necrosis factor (TNF). Symptoms may include fever, myalgia, change in mental status, 
hypotension, pulmonary infiltrates, metabolic acidosis and acute renal failure. Cytokine storm has 
been observed with an agonistic anti -CD28 antib ody (TGN1412), but is not expected with 
NIVOLUMAB and/or ipilimumab, and has not been observed in human subjects with cancer or 
hepatitis C treated to date.  
 Immune -related adverse events:  It is possible that syndromes may develop that are most 
consistent w ith an underlying enhanced immune response as the driving factor. Such events may 
consist of persistent rash, diarrhea and colitis, autoimmune hepatitis, arthritis, glomerulonephritis, 
or cardiomyopathy. Experience with ipilimumab indicates that irAEs are typically low grade and 
self limited, more often occur after multiple doses, and most frequently involve the GI tract 
(diarrhea/colitis), skin (rashes), liver (hepatitis), and endocrine systems (a variety of 
endocrinopathies). See. section 8. 5. 
 Gastrointes tinal system:  Colitis is characterized by new onset of diarrhea, which may be 
accompanied by abdominal pain and/or GI bleeding. Events of Grade 3 or Grade 4 diarrhea as well 
as Grade 2 diarrhea with blood in stool should be evaluated for colitis. Subjects should be 
instructed to report all events of diarrhea immediately to the Investigator.  Any  Grade  2 
diarrhea/colitis must be reported to the BMS, within 24  hours using the rapid notification 
procedures described in S ection 8.6 . 
 Inflammatory hepatotoxiciti es: Hepatotoxicity has been observed in the ipilimumab program, and 
in the concurrent NIVOLUMAB/ipilimumab study 58. Hepatocytes have been shown to express PD -
L1 in the setting of IFN - and may occur in the presence of inflammation due to chronic viral 
hepatitis or immune -related heightened reactivity. PD -1 blockade may result in enhanced hepatic 
inflammation.  
Protocol S16 -00098  Confidential  Page 27 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  Immune suppression:  Subjects should be monitored for signs of new infection or  return of a 
previous infection, with rash, fever, chills, other localizing symptoms, or sepsis that could require 
antibiotics either as prevention or treatment.  
 Musculoskeletal system:  Muscle or joint aches, swelling, or weakness.  
 Blood: A decrease in blo od components (platelets, white or red cells) that could lead to infection, 
bleeding, or anemia.  
 Heart: Irregular heart rhythm or heart attack.  
 Skin: The most likely adverse events are rash and pruritus, which generally resolve when study 
drug is discontin ued. 
Human anti -human antibodies: In preliminary analyses, emergence of anti -NIVOLUMAB 
antibodies following treatment has not been observed to date. Neutralizing antibodies have not been 
observed with the use of ipilimumab. Such antibodies were detected at  baseline (pre -treatment) in 4 
of 36  subjects treated with NIVOLUMAB (Protocol MDX1106 -01). The reactivity in 1 of these 
subjects was likely due to endogenous interference in the assay, as this subject had subsequent 
positi ve post -dose results. The other 3 subjects had negative post -dose results. In the 1  subject with 
positive baseline and post -baseline results, there appears to have been no impact of 
immunoreactivity on the safety of NIVOLUMAB.  
2.5. Study Duration  
The expected maximum duration of NIVOLUMAB  treatment for a subject is 1.25 years  (60 weeks) . 
Expected maximum duration of nivolumab with ipilimumab treatment is 12 weeks.  
The expected maximum duration of a subject’s participation in this study is 3 years with survival follow -
up to continue indefi nitely until withdrawal of consent for follow -up or death.  
3. STUDY POPULATION  
Up to 25 subjects may be enrolled. Subjects must meet all the inclusion criteria and none of the exclusion 
criteria to receive a treatment  assignment.  
3.1. Inclusion Criteria  
Subjects m ust meet the following criteria at Screening to be eligible to participate in the study.  
1. Be at least 16 years of age;   
2. Histologic diagnosis of resected Stages IIIB/ IIIC/ IV melanoma, with no evidence of disease 
clinically and radiologically , and negative s urgical margins . All melanomas regardless of primary 
site of disease will be allowed;  
3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (Appendix 2);  
4. Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to 
control the cancer) must have been completed at least 4 weeks before study drug administration, 
and all adverse events have either returned to baseline or stabilized;  
Protocol S16 -00098  Confidential  Page 28 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 5. Prior treated brain or meningeal metastases must be without magnetic resonance i maging (MRI) 
evidence of progression for at least 8  weeks and off immunosuppressive doses of systemic 
steroids (> 10 mg/day prednisone or equivalent) for at least 2 weeks before study drug 
administration;  
6. Prior systemic radiation therapy must have been com pleted at least 4 weeks before study drug 
administration. Prior focal radiotherapy completed at least 2 weeks before study drug 
administration. No radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug 
administration;  
7. Immunosuppressive  doses of systemic medications, such as steroids or absorbed topical steroids 
(doses > 10 mg/day prednisone or equivalent) must be discontinued at least 2  weeks before study 
drug administration;  
8. Completed nitrosourea treatment at least 6 weeks before admin istration of any study drug;  
9. Prior surgery that required general anesthesia must be completed at least 4 weeks before study 
drug administration. Surgery requiring local/epidural anesthesia must be completed at least 72 
hours before study drug administratio n and subjects should be recovered;  
10. Screening laboratory values must meet the following criteria:  
 white blood cells (WBCs)  ≥ 2000 cells/ L 
 neutrophils   ≥ 1500 cells/ L 
 platelets   ≥ 100 x 103/L 
 hemoglobin   ≥ 9.0 g/dL  
 serum creatinine    2 mg/dL  
 AST   ≤ 2.5 x upper limit of normal (ULN)  
   without, and ≤ 5 x ULN with hepatic  
   metastasis  
 ALT   ≤ 2.5 x ULN without, and ≤ 5 x ULN  
   with hepatic metastasis  
 bilirubin   ≤ 2 x ULN (except subjects with  
   Gilbert’s syndrome, who must have total  
   biliru bin < 3.0 mg/dL)  
11. Females of childbearing potential must:  
use appropriate method(s) of contraception.  WOCBP should use an adequate method to avoid 
pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half -lives) 
after the las t dose of investigational drug  
Women of childbearing potential must have a negative serum or urine pregnancy test (minimum 
sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab  
 
Protocol S16 -00098  Confidential  Page 29 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 12. For female subjects to be considere d as not having childbearing potential, they must meet 1 or 
more of the following criteria:  
 postmenopausal for at least 24 consecutive months;  
 surgically sterile (ie, have had a hysterectomy or bilateral oophorectomy);  
 females with irregular menstrual p eriods and/or on hormone replacement therapy must have a 
documented serum follicle stimulating hormone level > 35 mIU/mL;  
13. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate 
of less than 1% per year Men receiving ni volumab and who are sexually active with WOCBP will 
be instructed to adhere to contraception for a period of 31 weeks after the last dose of 
investigational product Women who are not of childbearing potential (ie, who are 
postmenopausal or surgically steri le as well as azoospermic men do not require contraception   
14. Subject must have read, understood, and provided written informed consent and HIPAA 
authorization after the nature of the study has been fully explained; and  
15. Willing to adhere to the study visit s chedule and the prohibitions and restrictions specified in this 
protocol.  
3.2. Exclusion Criteria  
Subjects who fulfill any of the following conditions at Screening will not be eligible for admission into 
the study:  
1. History of severe hypersensitivity reactions t o other mAbs;  
2. Prior non -melanoma malignancy active within the previous 2 years except for locally curable 
cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial 
bladder cancer, or carcinoma in situ of the prostate,  cervix or breast;  
3. Subjects with any active autoimmune disease (Appendix 3) or a documented history of 
autoimmune disease, or history of syndrome that required systemic steroids or 
immunosuppressive medications, except for subjects with vitiligo or resolve d childhood 
asthma/atopy;  
4. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired 
immunodeficiency syndrome (AIDS);  
5. Positive tests for hepatitis B virus surface antigen (HBV SAg) or hepatitis C virus ribonucleic 
acid (HCV  RNA) indicating active or chronic infection;  
6. Prior therapy with an anti -PD-1, anti -PD-L1, anti -PDL -2, or anti -CTLA -4 antibody (or any other 
antibody targeting T cell co -stimulation pathways);  
7. Concurrent medical condition requiring the use of immunosuppressive medications, or 
immunosuppressive doses of systemic or absorbable topical corticosteroids;  
Protocol S16 -00098  Confidential  Page 30 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 8. Underlying medical condition (eg, a condition associated with diarrhea) that, in the Investigator’s 
opinion, would make the administration of eithe r study drug or both study drugs hazardous to the 
subject or obscure the interpretation of toxicity determination or adverse events;  
9. Pregnant or nursing; or  
10. Current participation in another clinical study involving treatment with medications, radiation or 
surgery, or prior participation in this study.  
11. Patients are excluded if they have active brain metastases or leptomeningeal metastases. Subjects 
with brain metastases are eligible if metastases have been treated and there is no magnetic 
resonance imaging ( MRI) evidence of progression for [lowest minimum is 4 weeks or more]  
after treatment is complete and within 28 days prior to the first dose of nivolumab administration. 
There must also be no requirement for immunosuppressive doses of systemic corticostero ids (> 
10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.  
12. As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, 
drugs with a predisposition to hepatoxicity should be used wit h caution in patients treated with 
nivolumab -containing regimen.  
13. Allergies and Adverse Drug Reaction  
a. History of allergy to study drug components  
b. History of severe hypersensitivity reaction to any monoclonal antibody  
3.3. Inclusion of Women and Minorities  
 Both males and females  of all races and ethnic groups are eligible for this trial.   
3.4. Subject Recruitment and Screening  
The patients who are eligible for this research study come directly from the study investigators’ clinical 
patient population. Thus, the inves tigators are very familiar with their patients’ disease status and 
potential eligibility given the protocol’s inclusion and exclusion criteria. All efforts will be made to 
actively recruit and retain women and members of minority groups in this study .  The investigator will 
approach eligible potential subjects and explain the study in a private room, including the reasons why 
subjects will be eligible, risks, benefits, and the regimes to be evaluated.  The subjects will be given a 
chance to ask questions to  the person consenting him/her and will be able to take the consent home to 
discuss it with family/friends prior to signing. If the subject agrees s/he will sign the consent form either 
at the first contact (if the investigator/delegate is convinced that t he subject understands) or at the time of 
a return visit after having had time to study the consent in more depth. Study procedures will not begin 
until after the consent form has been properly obtained. The subject is entitled to decide not to participate  
in the trial, without affecting their right to other medical care, and may discontinue participation in the 
trial at any time without penalty or loss of benefits to which they are entitled .  
 
 
 
Protocol S16 -00098  Confidential  Page 31 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 3.4.1 Informed Consent  
Consent will be obtained only by an investigator who has completed requisite training for human subject 
research and has been instructed by the Principal investigator about the research study and consent 
process.   
The Investigator, or designee, will explain to each subject (or legally authorized representative) the nature 
of the research study, its purpose, the procedures involved, the expected duration of subject participation, 
alternative treatment, the potential risks and benefits involved and any discomfort which may occur 
during the subject’s participation in the study.  The Investigator will review the informed consent form 
with patients and address any questions or concerns prior to obtaining written informed consent for 
participation.  Each subject will be informed that participation in the study is voluntary and that he/she 
may withdraw from the study at any time and that withdrawal of consent will not affect his/her 
subsequent medical treatment or relationsh ip with the treating physician. For patients ages 16 -17, parents 
will sign the informed consent, and children will sign an Assent, which will accompany the Consent 
Form.   Children who turn 18 during the course of their participation will be approached to go through the 
full consenting process and be asked to provide written informed consent in order to continue 
participation.  
For non -English speaking patients, institutional translation services will be utilized. For these patients the 
consent letter and all other information will be administered orally and a witness, not related to the 
research project, will be present while the oral presentation is given. A short form will be utilized for the 
subject to sign in his/her name and the translator and/or witness must sign the short form. The translator 
will also sign the main consent form.  
 
For patients who cannot read. A witness, not related to the research study will be present. The consent 
will be read to the patient. The patient will also be allowed to ask any  questions s/he may have. The 
investigator will ask the patient questions to ensure s/he understands the study. If the investigator 
determines the subject understands the study, the patient will mark an X where his/her name would go 
and the witness will si gn the consent form.  
 
This informed consent should be given by means of a standard written statement, written in non -technical 
language. The subject should read and consider the statement before signing and dating it. The subject 
will be given a copy of th e signed document. The original signed consent document will be retained by 
the Investigator. If written consent is not possible, oral consent can be obtained if witnessed by a signed 
statement from 1 or more persons not involved in the study, attesting to the accuracy of the presentation, 
the apparent understanding of the subject and documenting why the subject was unable to read and sign 
the form. No subject can enter the study and no study -related procedures can be performed before his/her 
informed conse nt has been obtained.  
The ICF (that complies with regulatory requirements and is considered appropriate for the study) must be 
submitted by the Investigator with the protocol for IRB approval.  
 
 
Protocol S16 -00098  Confidential  Page 32 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 3.4.2 Documentation of Consent  
The Principal Investigator or IRB approved sub -investigator will be responsible for documentation in the 
medical record that consent has been obtained from all participants. A signed copy of the consent form 
will be given to each participant. Original consent forms will be stored in  the subject’s medical chart.  
 
3.4.3 Demographic/Medical History/Current Medical Conditions, and Laboratory 
Abnormalities  
 
Demographics and medical history will be obtained by the Investigator or designee during the Screening 
Period . Demographics will incl ude date of birth, sex, ethnicity, and race. Relevant medical history should 
be recorded and should include prior/current medical conditions, and clinically significant laboratory 
abnormalities (excluding study disease -related abnormalities).  All prior tr eatment for melanoma will be 
recorded. All non -melanoma medications used during the 28 days before the first dose of the study drugs 
will be recorded.  
 
3.4.4 Review Inclusion/Exclusion Criteria Including Concomitant Medication  
 
Inclusion and exclusion crit eria will be reviewed by the Investigator to ensure that the subject qualifies for 
the study at Screening . All appropriate medication washout times will be discussed with the subject and 
documented; the IC F must be signed before discontinuing any medicatio n. 
 
 
3.4.5 Registration Procedures  
3.4.5.1 General Guidelines  
Each patient must sign and date an informed consent form before undergoing any study specific 
procedure  unless a procedure is being performed as part of the patient’s standard of care.  
Enrollment in the study requires that all inclusion and exclusion criteria have been met.  Enrol lment 
occurs upon confirmation of registration from the NYULMC PCC Clinical Trials Office.  The following 
materials must be submitted to the Research Coordinato r for registration:  
1.  Complete signed and dated informed consent form  
2. Complete signed and dated informed consent checklist  
3. Complete signed and dated eligibility checklist  
4. All supporting documentation verifying each criterion has been met  
 
Registration will occur within 24 hours of research coordinator receipt of all of the above documents.  A 
written confirmation of enrollment including a unique study identification number assigned by the 
research coordinator will be distinguished to th e study team upon regi stration.  
Pretreatment evaluation will therefore be as directed by standard clinical practice.  Eligible subjects will 
be entered on study by the study coordinator.  
Protocol S16 -00098  Confidential  Page 33 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 All patients will be required to sign a written informed consent prior to being registered on this study.  
Every effort will be made to answer questions raised by patients and their families or advocates regarding 
the protocol and alternative therapies prior to asking a pati ent to sign the consent form.   
Once eligibility is verified, a unique p atient study number will be issued within 24 hours of receiving all 
required registration material.  The patient will not be identified by name.  This is the point, at which, the 
patient is considered on study.  Subjects must not start any protocol procedu res prior to registration.  
3.4.6 Early Discontinuation Criteria and Procedures  
3.4.6.1  Discontinuation of Study Drug  
It is the right and duty of the Investigator to discontinue the study drugs of any subject if he feels that 
discontinuation of the study drugs is necessary to protect the subject, or that there are unmanageable 
factors that may interfere significantly with the study procedures and/or the interpretation of results.  
Administration of the study drugs will be discontinued if the subject develop s a DLT, documented 
relapse, or other intolerability to the study drugs.  
Administration of the study drugs may be discontinued during the study for any of the following reasons:  
 Adverse event(s)  
 Protocol violation  
 Subject withdrew consent  
 Lost to follow -up 
 Other  
 Death  
For subjects who discontinue the study drugs for any reason, the remaining study visits and associated 
evaluations (without dosing) should be completed. Patients who discontinue the study drug(s) due to a 
toxicity will be followed until the t oxicity resolves to baseline. Patients will continue to be followed on 
the protocol schedule for radiology assessments and for relapse free survival. Pharmacokinetic samples 
will only be collected at the visit following study drug discontinuation.  
All sub jects will be followed for adverse events for at least 70 days after the last dose of study drugs and 
for survival follow -up indefinitely until withdrawal of consent or death.  
3.4.6.2  Discontinuation from the Study  
Subject participation in the study may be  discontinued for any of the following reasons:  
 Adverse event(s)  
 Protocol violation  
 Subject withdrew consent  
 Lost to follow -up 
 Disease relapse  
Protocol S16 -00098  Confidential  Page 34 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  Death  
 Other  
For subjects who discontinue the study for any reason, all evaluations associated with the Study 
Comp letion/Early Withdrawal visit should be performed. All subjects will be followed for adverse events 
for at least 70 days after the last dose of study drugs.  
If a subject withdraws consent for study participation, every attempt will be made to determine th e reason. 
These subjects will be asked to allow survival follow -up contacts. Subject completion status (completed 
versus not completed) will be documented.    
For subjects who discontinue from the study without completing the Study Completion/Early Withdraw al 
visit, only study drug -related adverse events will be collected.  
4. TREATMENTS  
On days when both study drugs will be administered, NIVOLUMAB  will be administered before 
starting the ipilimumab infusion . 
4.1. Description of NIVOLUMAB  with ipilimumab Treatment  
NIVOLUMAB  will be supplied as a sterile, preservative -free solution in 10  mL vials at a concentration of 
10 mg/mL; which, based on the subject’s weight, may be diluted with sterile normal saline (0.9%  sodium 
chloride). NIVOLUMAB  (1, 3, or 10 mg/kg) will be a dministered as a 30-minute i.v. infusion.  Although 
NIVOLUMAB  has been infused generally over 60 minutes, a series of 20 patients have received the drug 
at 3 mg/kg or 10 mg/kg over 30 minutes without any increase in infusion reactions. Therefore , it is felt 
safe to administer NIVOLUMAB  in this study  over 30 minutes.  
Ipilimumab will be supplied as a sterile, preservative -free solution in 40  mL (200 mg) vials at a 
concentration of 5 mg/mL; which, based on the subject’s weight and dose level assignme nt, may be 
diluted with sterile normal saline (0.9%  sodium chloride). Ipilumumab (3 mg/kg) has been  administered 
as a 90 -minute i.v. infusion. Since ipilimumab wi ll be given at 1 mg/kg in this study , one third the dose 
previously used , it is felt appropria te to shorten the 90 minute infusion to 30 minutes, since the infusion 
rate will not change.  
BMS, Inc. will manufacture and supply NIVOLUMAB  and ipilimumab to the Sponsor -investigator . 
4.2. Treatment Regimen  
 
4.2.1 Toxicity management  
4.2.1.1.  Management:  
For Grade 1 and 2 adverse events felt due to NIVOLUMAB or NIVOLUMAB with ipilimumab, 
symptomatic treatment is called for generally without a dose delay. For selected irAEs of grade II, 
especially colitis and ophthalmologic toxicity, one dose of NIVOLUMAB o r NIVOLUMAB with 
Protocol S16 -00098  Confidential  Page 35 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 ipilimumab may be skipped until resolution of the toxicity to Grade 1 or less. Grade 3 irAEs that 
constitute dose limiting toxicity will cause treatment with NIVOLUMAB or NIVOLUMAB with 
ipilimumab to be discontinued permanently. For grade III irAEs that do not constitute DLT, do not 
require more than 2 weeks of systemic steroid treatment , and resolve within 28 days to grade I or less, 
with either one or no skipped doses, therapy with NIVOLUMAB or NIVOLUMAB with ipilimumab may 
continue at th e same dose(s).  There will be no dose reductions of NIVOLUMAB for an individual 
patient.  Management of infusion rea ctions is defined in section 5.2.2  below . 
4.2.1.2.  Dose Delay:  
NIVOLUMAB with ipilimumab administration should be delayed for the following:  
 
 Any Grade ≥2 non -skin, drug -related adverse event, with the following exceptions:  
 
o Grade 2 drug -related fatigue or laboratory abnormalities do not require a treatment delay  
 
 Any Grade 3 skin, drug -related adverse event  
 
 Any Grade 3 drug -related laboratory abnormality, with the following exceptions for AST, ALT, 
total bilirubin, amylase and lipase:  
 
o If a subject has a baseline AST, ALT, or total bilirubin that is within normal limits, delay  
dosing for drug -related Grade ≥ 2 or greater  toxicity  
 
o If a subject has baseline AST, ALT, or total bilirubin within the Grade 1 toxicity range,  
delay dosing for drug -related Grade ≥ 3 or greater  toxicity  
 
o Grade 3 amylase or lipase abnormalities that are not associated with symptoms or clinical 
manifestations of pancreatit is do not require a dose delay. It is recommended to consult 
with the BMS Medical Monitor for Grade 3 amylase or lipase abnormalities.  
 
 Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of the 
investigator, warrants delaying the dose of study medication.  
 
Because of the potential for clinically meaningful nivo lumab or ipilimumab related AEs requiring early 
recognition and prompt intervention, management algorithms have been developed for suspected 
pulmonary toxicity, GI, hepatotoxicity, endocrinopathy, skin toxicity, neurological toxicity and 
nephrotoxicity. For the overlapping adverse event management algorithms present in both the 
NIVOLUMAB  and ipilimumab IB ( GI, hepatic, and endocrine algorithms), the recommendation s are to 
follow the NIVOLUMAB  IB adverse event algorithms as opposed to the ipilimumab IB algorithms.  
 
Subjects may resume treatment with study drug (s) when the drug -related AE(s) resolve to Grade 1 
or baseline value, with the following exceptions : 
  
 Subjects may resume treatment in the presence of Grade 2 fatigue  
Protocol S16 -00098  Confidential  Page 36 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  Subjects who have not experienced a Grade 3 drug -related skin AE may resume treatment 
in the presence of Grade 2 or less skin toxicity  
 Subjects with baseline Grade 1 AST/ALT or total bilirubin who require dose delays for 
reasons other than a 2 -grade shift in AST/ALT or total bilirubin may resume treatment in 
the presence of Grade 2 AST/ALT OR total bilirubin  
 Subjects with combined Grade 2  AST/ALT AND total bilirubin values meeting 
discontinuation parameters should have treatment permanently discontinued  
 Drug -related pulmonary toxicity, diarrhea, or colitis, must have resolved to baseline before 
treatment is resumed  
 Drug -related endocrinopa thies adequately controlled with only physiologic hormone 
replacement may resume treatment  
 
If the criteria to resume treatment is met, the subject should restart treatment at the next  scheduled 
timepoint per protocol. However, if the treatment is delayed past the next scheduled timepoint per 
protocol, the next scheduled timepoint will be delayed until dosing resumes. If treatment is delayed 
greater than 6 weeks, the subject must be permanently discontinued from study treatm ent, except as 
specified in the d iscontinuation section below.  
 
4.2.1.3.  Discontinuation  
Treatment should be permanently discontinued for the following:  
 
 Any Grade 2 drug -related uveitis or eye pain or blurred vision that does not respond to 
topical therapy and does not improve to Grade 1 severity  within the re -treatment period OR 
requires systemic treatment  
 
 Any Grade 3 non -skin, drug -related adverse event lasting > 7 days, with the 
following  exceptions for drug -related laboratory abnormalities, uveitis, pneumonitis, 
bronchospasm, diarrhea, coliti s, neurologic toxicity, hypersensitivity reactions, and infusion 
reactions:  
 
 Grade 3 drug -related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, neurologic  
       toxicity, hypersensitivity reaction, or infusion reaction of any duration requires  
       discontinuation  
 
Grade 3 drug -related laboratory abnormalities do not require treatment discontinuation  
except:  
 
 Grade 3 drug -related thrombocytopenia > 7 days or associated with bleeding requires  
Discontinuation  
 
 Any drug -related liver function test (LFT) abnormality that meets the following  
criteria require discontinuation:  
 
o AST or ALT > 8 x ULN  
o Total bilirubin > 5 x ULN  
Protocol S16 -00098  Confidential  Page 37 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 o Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN  
 Any Grade 4 drug -related adverse event or laboratory abnormality , except for the 
following events which  do not require discontinued.  
o Isolated Grade 4 amylase or lipase abnormalities that are not associated with 
symptoms or clinical manifestations of pancreatitis.   It is recommended to 
consult with the BMS Medical Monit or for grade 4 amylase or lipase 
abnormalities.  
o Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with 
clinical sequelae and are corrected with supplementation/appropriate 
management within 72 hours of their onset  
 Dosing interruptions to allow for prolonged steroid tapers to manage drug -related adverse 
events are allowed. Prior to re -initiating treatment in a subject with a dosing interruption 
lasting > 6 weeks, the BMS medical monitor must be consulted. Tumor assessments should 
continue as per protocol even if dosing is interrupted.  
 
 Dosing interruptions > 6 weeks that occur for non -drug-related reasons may be allowed if 
approved by the BMS medical monitor. Prior to re -initiating treatment in a subject with a 
dosing interr uption lasting > 6 weeks, the BMS medical monitor must be consulted. Tumor 
assessments should continue as per protoco l even if dosing is interrupted.  
 
Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of the 
Investig ator, presents a substantial clinical risk to the subject with continued NIVOLUMAB or 
NIVOLUMAB and ipilimumab dosing.  
 
4.2.1.4.  Dose Adjustments, Dose Delays, and Missed Doses  
There will be no dose adjustments allowed except if there has been  10% weight change s ince the 
previous treatment  (cycle 1)  visit. There will be no dose adjustments for ipilimumab. Starting 4 weeks 
after the last co -administered dose in cycle 1, subjects will be administe red a flat dose 480 mg 
NIVOLUMAB  IV every 4 weeks (Q4W) in cycles 2 -5 and there will be no dose adjutsments for weight.  
During the Induction Treatment Period  (cycle 1)  and Treatment/Follow -up periods  (cycles 2 -5), if there is 
a dose delay between 1 and 7 days, the procedures at the original scheduled visit should be perfor med as 
soon as possible. If the delay is more than 7  days, the visit and dose will be considered missed; the 
procedures at the next scheduled visit should be performed, and subsequent visits will follow every 2 
weeks. Subjects with infusion delays > 35 day s (ie,  2 missed doses + 7  days) should discontinue the study 
drugs and complete the remaining study visits (without dosing).  
Protocol S16 -00098  Confidential  Page 38 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 4.2.2.  Infusion Reactions  
NIVOLUMAB and/or ipilimumab  may induce infusion or hypersensitivity reactions. If such a reaction 
were to occur, it may manifest with fever, chills, rigors, headache, rash, pruritus, arthralgias, hypo - or 
hypertension, bronchospasm, or other symptoms.  
Infusion reactions should be gr aded according to Common Terminology Criteria for Adverse Events 
(CTCAE, Version 4.0) guidelines. Treatment recommendations are provided below and may be modified 
based on clinical judgment, local treatment standards and guidelines, and/or specific symptom s, as 
appropriate:  
For Grade 1 symptoms:  (Mild reaction [eg, localized cutaneous reactions including mild pruritus, 
flushing, rash.] requires infusion rate to be decreased; intervention may be indicated)  
 Decrease the rate of the NIVOLUMAB and/or ipilimumab  infusion until recovery from symptoms.  
 Remain at bedside and monitor subject until resolution of symptoms. Diphenhydramine 50  mg, may 
be administered at the discretion of the treating physician.  
 When symptoms resolve, restart the infusion at the original infusion rate.  
 If a subject has an infusion reaction with NIVOLUMAB and/or ipilimumab, prophylactic 
preinfusion medications should be given prior to all subsequent NIVOLUMAB and/or ipilimumab 
infusions.  
 The following prophylactic preinfusion medications a re recommended prior to future infusions of 
NIVOLUMAB and/or ipilimumab: diphenhydramine 50  mg (or equivalent) and/or paracetamol 
325 to 1000  mg (acetaminophen) at least 30  minutes before additional NIVOLUMAB and/or 
ipilimumab infusions.  
For Grade 2 sympto ms: (Moderate reaction [ie, any symptom not listed above (mild symptoms) or 
below (severe symptoms) such as generalized pruritus, flushing, rash, dyspnea, hypotension with systolic 
blood pressure > 80  mm Hg], requires infusion interruption but responds pro mptly to symptomatic 
treatment [eg, antihistamines, non -steroidal anti -inflammatory drugs, narcotics, corticosteroids, i.v. 
fluids]; prophylactic preinfusion medications indicated for ≤ 24 hours)  
 Discontinue the NIVOLUMAB and/or ipilimumab infusion.  
 Begin an i.v. infusion of normal saline, and treat the subject with diphenhydramine 50  mg i.v. (or 
equivalent) and/or paracetamol 325  to 1000  mg (acetaminophen).  
 Remain at bedside and monitor subject until resolution of symptoms. Corticosteroid therapy may  be 
administered at the discretion of the treating physician.  
 When symptoms resolve, restart the infusion at 50% of the original infusion rate; if no further 
complications ensue after 30  minutes, the rate may be increased to 100% of the original infusion 
rate. 
Protocol S16 -00098  Confidential  Page 39 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  Monitor subject closely. If symptoms recur, immediately discontinue the infusion; no further 
NIVOLUMAB and/or ipilimumab will be administered at that visit. Administer diphenhydramine 
50 mg i.v., and remain at bedside and monitor the subject until re solution of symptoms.  
 If a subject has an infusion reaction with NIVOLUMAB and/or ipilimumab, prophylactic 
preinfusion medications should be given prior to all subsequent NIVOLUMAB an/or ipilimumab 
infusions.  
 The following prophylactic preinfusion medicat ions are recommended prior to future infusions of 
NIVOLUMAB and/or ipilimumab: diphenhydramine 50  mg (or  equivalent) and/or paracetamol 
325 to 1000  mg (acetaminophen) should be administered at least 30  minutes before additional 
NIVOLUMAB and/or ipilimumab administrations. If necessary, corticosteroids (up to 25 mg of 
SoluCortef or equivalent) may be used.  
 The amount of NIVOLUMAB and/or ipilimumab infused must be recorded.  
For Grade 3 or Grade 4 symptoms : (Severe reaction [eg, bronchospasm, generalized urtic aria, systolic 
blood pressure  80 mm Hg, or angioedema], Grade 3: prolonged [ie, requiring 6 or more hours to 
respond to symptomatic medication and/or discontinuation of infusion]; recurrence of symptoms 
following initial improvement; hospitalization indi cated for other clinical sequelae [eg,  renal impairment, 
pulmonary infiltrates]. Grade 4: life -threatening; pressor or ventilatory support indicated).  
 Immediately discontinue the NIVOLUMAB and/or ipilimumab infusion. No further NIVOLUMAB 
or ipilimumab will  be administered. The amount of NIVOLUMAB and/or ipilimumab infused must 
be recorded.  
 Begin an i.v. infusion of normal saline, and treat the subject as follows: Recommend 
bronchodilators, epinephrine 0.2 to 1.0 mg of a 1:1,000  solution for subcutaneous adm inistration or 
0.1 to 0.25 mg of a 1:10,000 solution injected slowly for i.v. administration, and/or 
diphenhydramine 50  mg i.v. with methylprednisolone 100 mg i.v. (or equivalent), as needed.  
 Remain at bedside and monitor subject until recovery from sympt oms.  
 Subject should be monitored until the Investigator is comfortable that the symptoms will not recur.  
 The Investigator should follow the institutional guidelines for the treatment of anaphylaxis.  
In the case of late -occurring hypersensitivity symptoms (eg, appearance of a localized or generalized 
pruritus within 1  week after treatment), symptomatic treatment may be given (eg,  oral antihistamine, or 
corticosteroids).  
4.2.3.  Treatment Reactions:  Definitions, Monitoring, and Management  
Potential toxicities inclu ding infusion and post -infusion reactions were defined above for NIVOLUMAB 
and/or ipilimumab (Section 5.2.2 ). These events will be closely monitored.  
Therapy to prevent or treat local and/or systemic reactions following either study drug administration may  
include analgesics, antipyretics and antihistamines. Additionally, if necessary, corticosteroids may be 
temporarily added or increased for up to 7 days after study drug(s) administration.  
Protocol S16 -00098  Confidential  Page 40 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 4.2.4.  Dose Limiting Toxicity:  Definition, Monitoring, Management  
(Versi on 4.0 of the NCI Common Terminology Criteria for Adverse Events ( CTCAE) will be utilized for 
AE reporting.   Version 4.0 of the CTCAE is identified and located on the CTEP website at 
HTTP://CTEP.CANCER.G OV/PROTOCOLDEVELOPME NT/ELECTRONIC_APPLIC ATIONS/
CTC.HTM .  All appropriate treatment areas should have access to a copy of Version 4.0 of CT CAE.)  
4.2.4.1.  Definition  
A DLT is defined as a NIVOLUMAB or NIVOLUMAB with ipilimumab  related Grade 3  or greater  
adverse event other than the exceptions noted occurring within 29 days after the first dose excluding: 
Grade 3 adverse event of tumor flare (defined as  local pain, irritation, or rash localized at sites of known 
or suspected tumor), Grade 3 rash, Grade 3 immune -related adverse event (irAE, defined below) that 
resolves to a Grade 1 or less within 28 days, or a transient (resolving within 6 hours of onset)  Grade 3 
infusion -related adverse event. A Grade 3 irAE that resolves to a Grade 1 or less within 28 days, while 
not constituting a DLT for dose escalation purposes, may preclude further administration of 
NIVOLUMAB and/or ipilimumab  to the subject.  
The fol lowing are excluded from the definition of a DLT:  
 Grade 3 rash,  
 Grade  3 irAE that resolves to a Grade 1 or less within 28 days, or  
 A transient (resolving within 6 hours of onset) Grade 3 infusion -related adverse event.  
 
A Grade 3 irAE  that resolves to a Grade 1 or less within 28 days, while not constituting a DLT, may 
preclude further administration of the study drugs to the subject. A DLT will be considered related to 1 or 
both study drugs unless there is a clear, well -documented, alt ernative explanation for the toxicity. 
Toxicities occurring more than 28 days after the first dose will be monitored and discussed with BMS.  
 
All adverse events that meet DLT criteria, as well as any Grade 3 or 4 infusion reactions whether or not 
the event  is a DLT , must be reported using the rapid notification procedures described in Section 9.6.  
Patients who discontinue treatment for toxicities will continue on the protocol radiology evaluation 
schedule every 12 weeks once the toxicity resolves to obtain relapse -free survival data.  
 
4.2.5.  Stopping Rules for Dose -limiting Toxicity  
If 3 or more of the first 6  subjects or 4 or more  of the first 10 or 40% of subjects or more in this cohort of 
20 patients experiences a DLT during Cycle 1,  accrual will stop pending consultations between the 
sponsor, BMS and the FDA.   
Protocol S16 -00098  Confidential  Page 41 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 4.2.5.1.  Other Stopping Rules During Enrollment  
Enrollment will be held at any time during the study if either of the following study drug -related, Grade 4 
or 5 toxicities occurs:  
 colitis with perforation and/o r requiring colectomy, or  
 hepatic failure.  
The Sponsor -investigator  will discuss such cases with BMS to decide whether to resume enrollment 
and/or to jointly discuss such cases with the FDA. IRBs will be notified by the Sponsor -investigator  of all 
cases an d decisions regarding continued enrollment.  
 
4.2.6.  Stopping Rules for Clinical Deterioration  
Accumulating clinical evidence indicates that the emergence of objective responses to agents that activate 
anti-tumor immune responses may follow delayed kinetics of wee ks or months, and can be preceded by 
initial apparent progression with appearance of new lesions or some enlarging lesions while certain index 
lesions are regressing (“mixed response”). It is thus reasonable to allow subjects experiencing apparent 
relapse in this trial to continue to receive treatment until relapse is confirmed at the next imaging 
assessment. These considerations should be balanced by clinical judgment as to whether the subject is 
clinically deteriorating and unlikely to receive any benefit  from continued treatment.  
Such deterioration will be assessed to have occurred after a clinical event that, in the Investigator’s 
opinion, is attributable to disease relapse, is unlikely to reverse with continued study treatment and 
therefore indicates th at the subject is not benefiting from study treatment Examples of events that may, in 
the Investigator’s opinion, indicate a lack of clinical benefit include, but are not limited to, the following:  
 Performance status decrease of at least 2 points from baseline.  
 Skeletal related events defined by the following:  
 pathologic bone fracture in the region of cancer involvement,  
 cancer related surgery to bone, and  
 spinal cord or nerve root compression.  
 Development of new central nervous system metastases.  
 
Or any setting where the initiation of new anti -neoplastic therapy has been deemed beneficial to the 
subject even in the absence of any such documented clinical events.  
4.3. Method for Assigning Subjects to Treatment group  
Up to 25 subjects (20 in this trial wit h five to account for drop -outs) will be enrolled in the study.  All 
subjects will receive the same treatment regimen.  
Protocol S16 -00098  Confidential  Page 42 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 4.4. Preparation and Administration of Study Drug  
NIVOLUMAB  will be given at the following dosages: 3  mg/kg  in cycle 1; s tarting 4 weeks after the last 
co-administered dose in cycle 1, subjects will be administe red a flat dose 480 mg NIVOLUMAB  IV 
every 4 weeks (Q4W) in cycles 2 -5.  
Ipilimumab will be given at the following dosage: 1 mg/kg  
NIVOLUMAB  will be administered before ipilimumab  in cycle  1.  
NIVOLUMAB  and/or ipilimumab will be administered as an i.v. infusion, using a volumetric pump with 
a 0.2  micron in -line filter at the protocol -specified dose(s) and rate. NIVOLUMAB  and/or ipilimumab are 
not to be administered as an i.v. push or bolus injection. No incompatibilities between NIVOLUMAB  
and/or ipilimumab and polyolefin bags have been observed.  
4.4.1 Preparation  
As NIVOLUMAB  and ipilimumab are stored at refrigerated temperatures (2  to 8C), allow the 
appropriate number of vials to stand at  room temperature for approximately 5 minutes.  
1. Ensure that the solution is clear, colorless and free from particulate matter on visual inspection. If 
multiple vials are needed for a subject, it is important to use a separate sterile syringe and needle 
for each vial to prevent problems such as dulling of needle tip, stopper coring, repeated friction of 
plunger against syringe barrel wall, etc. Do not enter into each vial more than once. Any partial 
vials should be safely discarded per the site standard opera ting procedures (SOPs) and should not 
be re -used.  
2. Aseptically withdraw the required volume of NIVOLUMAB  and/or ipilimumab into a syringe 
and place into an empty i.v. bag. For patients during ther Induction Treatment cycle 1 only, b ased 
on the subject’s weight, the concentrated NIVOLUMAB  and/or ipilimumab solution may be 
diluted with sterile normal saline (0.9%  sodium chloride) for a total volume of 60 mL. In cases 
where the total volume is more than 60  mL, no additional dilution is necessary. For patients 
receiving flat dosing of 480 mg NIVOLUMAB in cycles 2 -5, there will be no dilution.  
3. Mix by GENTLY inverting several times. DO NOT shake.  
4. Visually inspect the final solution. If the infusion is not clear or the contents appear to con tain 
precipitate, BMS should be notified, the solution discarded and the information documented.  
5. Record the time that the study drug was prepared on the i.v. bag label(s).  
 
4.4.2 Administration  
NIVOLUMAB  and/or ipilimumab should be administered under the s upervision of a physician 
experienced in the use of i.v. agents. NIVOLUMAB  and/or ipilimumab are not to be administered as an 
i.v. push or bolus injection. Prophylactic medications administered preinfusion, as described in Section 
Protocol S16 -00098  Confidential  Page 43 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 5.2.2 , may be given if a subject had a reaction during a previous NIVOLUMAB  and/or ipilimumab 
infusion.  
NIVOLUMAB  and/or ipilimumab should be administered as follows:  
 Attach the i.v. bag containing the NIVOLUMAB  and/or ipilimumab solution to the infusion set, 
0.2 μM in -line filter, and infusion pump.  
 The infusion rate of the infusion pump should be adjusted to allow for a total infusion time of 
30 minutes for NIVOLUMAB   , and 30 minutes for ipilimumab    
 At the end of each infusion, flush the line with an adequa te amount of normal saline.  
4.5. Subject Compliance Monitoring  
 
NIVOLUMAB and/or ipilimumab will be administered at the study site an d recorded on the case report 
form (CRF) and captured in Velos.  Subjects will be administered NIVOLUMAB and/or ipilimumab in a 
hospital setting under the supervision of appropriate study personnel.  Radiation therapy will be 
administered at the study site .  Subjects who are significantly non -compliant may be withdrawn from the 
study by the investigator and/or sponsor -investigator .  The investigator and/or sponsor -investigator  have 
the right to discontinue a subject from study treatment or withdraw a subjec t from the study at any time . 
4.6. Concomitant Therapy  
 
All medications taken within 28 days before the administration of the first dose of any study drugs and all 
concomitant therapy administered during the study until 70 days after last dose of any study drug  will be 
recorded, along with the reason for and details of therapy use.  
Information on all prior and concomitant therapy for melanoma, including chemotherapies, 
biochemotherapies, immunotherapies, radiation, surgery, biologics, and experimental therapy wi ll be 
collected.  
No concomitant medication information will be collected following subject discontinuation from the 
study except for concomitant medication use associated with study drug -related adverse events or adverse 
events that lead to discontinuation  from the study.  
4.6.1.  Permitted Therapy  
Subjects will be permitted topical or systemic concomitant treatment with prednisone ≤  10 mg/day (or 
equivalent). Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if 
the subject is on a stable dose. Non -absorbed int ra-articular steroid injections will be permitted. Systemic 
corticosteroids required for the control of infusion reactions or irAEs must be tapered and be at non -
immunosuppresive doses (≤ 10 mg/day of prednisone or equivalent) for at least 2 weeks before t he next 
study drug administration.  
Protocol S16 -00098  Confidential  Page 44 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Efforts should be made to keep all other concurrent medications at stable doses during the study and to 
refrain from starting any new medications, unless clinically indicated.  
Therapy to prevent or treat local and/or sys temic reactions following the infusion of either study drug may 
include analgesics, antipyretics and antihistamines. Additionally, if necessary, corticosteroids may be 
temporarily added or increased for up to 7 days post -infusion. Other therapies considere d necessary for 
the subject’s well -being may be administered at the discretion of the Investigator.  
4.6.2.  Prohibited Therapy  
The following medications are prohibited during the course of the study:  
 other anticancer agents  
 immunosuppressive agents  
 immunosuppressi ve doses of systemic steroids or topical steroids whose absorption is expected to 
result in systemically immunosuppressive steroid levels  
 other investigational drugs  
 non-oncologic vaccines (during the Treatment Period and within 4 weeks of any dose in the and 
Treatment/Follow -up Period)  
4.7. Packaging and Labeling     
NIVOLUMAB and/or ipilimumab will be packaged and labeled according to current good manufacturing 
practice requirements. The labels for NIVOLUMAB and/or ipilimumab  will be supplied by BMS and will 
bear BMS’s name and address, the storage conditions, lot number, the quantity of investigational product, 
and the standard caution statement, as follows: “Caution: New Drug - Limited by Federal Law to 
Investigational Use.”  
4.8. Storage  
NIVOLUMAB and/or ipilimumab vials must be stored at a temperature of 2 degrees Celsius to 8 degrees 
Celsius in a refrigerator in a locked facility. NIVOLUMAB and/or ipilimumab solution should be stored 
in the carton, protected from light, and mus t not be frozen. Recommended safety measures for preparation 
and handling of NIVOLUMAB and/or ipilimumab include the use of laboratory coats and gloves. Care 
must be taken to assure sterility of the prepared solutions as the products do not contain any ant i-
microbial preservative or bacteriostatic agent. Discard unused portions according to institutional 
procedures.  
Stability data supports the storage of diluted or undiluted (removed from the vial and prepared for 
administration) NIVOLUMAB and/or ipilimumab  for 18  hours at 2 degrees Celsius to 8 degrees Celsius 
and/or 6  hours at room temperature and normal room light. Note: once NIVOLUMAB and/or ipilimumab 
has been prepared for administration, the total storage time (combination of refrigeration and room 
temperature) is not to exceed 24  hours.  
Protocol S16 -00098  Confidential  Page 45 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 4.8.1.  Drug Accountability  
Study drug supplies must be kept in an appropriate, secure area (eg, locked) and stored in accordance with 
the conditions specified on the labels and in Section 5.8.  
The Investigator or designated s tudy person must maintain a log of study drug disposition including the 
amount of each study drug received, dosages prepared, doses dispensed, and doses and/or vials used or 
destroyed.  
At the conclusion of the study, and as appropriate during the course of  the study, the Investigator will 
destroy all other used and partially used study drugs in accordance with the site’s Standard Operating 
Procedures (SOPs). The Investigator will discard all unused NIVOLUMAB and/or ipilimumab with a 
copy of the completed NI VOLUMAB and ipilimumab drug disposition forms sent to BMS.  
4.9. Replacement of Subjects  
Subjects enrolled and  those  not treated will be replaced. A subject who is withdrawn from the study 
before the completion of the first cycle for a reason other than a DLT w ill also be replaced.  
5. STUDY PROCEDURES /EVALUATIONS  
The study is divided into 4  periods: Screening (up to 4 weeks), Induction Treatment (a 12 -week cycle), 
Treatment/Follow -up (cycles 2 -5, up to 48 additional weeks ), and Survival Follow -up with associated 
evaluations and procedures that must be performed at specific time points. The follow -up period has been 
extended indefinitely to include the Survival Follow -up period for overall survival, post -study treatment 
modalities, time to relapse, and site of relapse. The Screening Period is defined as the 28  days following 
initiation of screening assessments and before administration of any study drug, during which subjects are 
evaluated for study eligibility.  
The schedul e of study procedures and dosing frequency are shown in the Time and Events Schedule 
(Table  1). A description of individual study procedures is provided in the following subsections. For 
details of the procedures for assessment and reporting of adverse ev ents, see Section  8. 
5.1. Screening Procedures  
After providing informed consent, subjects will undergo screening for eligibility to participate in the 
study.   
5.1.1.  Physical Examination  
A physical examination will be performed at all visits. All abnormal findings at  baseline will be recorded 
as medical history. Any physical examination finding that is judged by the Investigator as a clinically 
significant change (worsening) compared to a baseline value will be considered an adverse event, and will 
be recorded and mon itored as described in Section  9. 
5.1.2.  Vital Signs  
Vital sign measurements include:  
Protocol S16 -00098  Confidential  Page 46 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  Temperature (°C)  
 Pulse (beat/minute)  
 Resting systolic and diastolic blood pressure (mmHg)  
 Height (cm)  
 Weight (kg)  
Before pulse and blood pressure are measured, the subject should be in a sitting  position and resting for at 
least 5  minutes. Vital signs are to be measured in accordance with the schedule of procedures shown in 
the Time and Events Schedule (Table 1).  
In the event of an infusion reaction, the infusion may be temp orarily stopped, slowed or discontinued, 
during which time vital signs should be monitored and recorded every 15  minutes until the infusion is 
completed, or if study drug is discontinued, the subject is stable. The frequency of vital sign 
measurements nece ssary to monitor an adverse event will be determined by the Investigator.  
Any vital sign value that is judged by the Investigator as a clinically significant change (worsening) 
compared to a baseline value will be considered an adverse event, recorded and monitored as described in 
Section  8. 
5.1.3.  Performance Status Assessment  
An assessment of performance status will be performed using the ECOG performance status scale of 0 to 
5 (Appendix 2).  
 
5.1.4.  Safety  
The overall safety and tolerability of NIVOLUMAB in combination with ipilimumab will be evaluated 
through an ongoing review of the incidence and severity of adverse events, clinical laboratory tests (blood 
and urine sampling for clinical laboratory paramet ers), physical examination results including vital sign 
measurements, ECOG evaluation, ECG, and chest radiography. Evaluations of immune safety tests and 
immunogenicity will also be performed  
5.1.5.  Adverse Events and Concomitant Medications  
Adverse events  and co ncomitant medication use will be collected thr oughout the study. See Section  8, 
Adverse Event Reporting, and Section 5.6, Concomitant Therapy for detail s. 
5.1.6.  Clinical Laboratory Tests  
Samples for chemistry, hematology, and urinalysis will be taken at the times indicated on the Time and 
Events Schedule (Table 1) and results must be reviewed before dosing to evaluate whether or not a 
subject should be treated at that visit. Minimum requir ed laboratory testing prior to each dose in all 
cycles: Within 72 hrs prior to re -dosing to include CBC w/ differential, LFTs, BUN or serum urea level, 
creatinine, Ca, Mg, Na, K, Cl, LDH, Glucose, amylase, lipase, TSH (with reflexive Free T4 and Free T3  
Protocol S16 -00098  Confidential  Page 47 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 if needed ). A laboratory abnormality is considered an adverse event if it results in discontinuation from 
the study drugs, necessitates therapeutic medical intervention, or if the Investigator assesses the 
abnormality as an adverse event as described in Sect ion 8. 
 
Protocol S16 -00098  Confidential  Page 48 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 5.1.6.1.  Chemistry  
Chemistry tests, including the following, will be performed:  
 albumin   chloride  
 alkaline phosphatase   creatinine  
 ALT   glucose  
 AST   potassium  
 bicarbonate   sodium  
 bilirubin (total)   total protein  
 calcium   urea nitrogen  
 amylase   lipase  
5.1.6.2.  Hematology  
Hematology tests, including the following, will be performed:  
 complete blood counts   absolute lymphocyte count  
 hemoglobin   hematocrit  
 differential counts   direct platelet count  
5.1.6.3.  Urinalysis  
The urinalysis will include testing for the following:  
 protein   glucose  
 specific gravity   blood (hemoglobin)  
 microscopic  (If gross findings are positive, then a microscopic examination including WBCs/high 
power field (HPF), and red blood cells/HPF, will be performed.)  
5.1.6.4.  Other  
Hepatitis Test  
Test for HBV SAg  and HCV antibody will be conducted at Visit 1. Results indicating active or chronic 
infection will result in study exclusion.  HCV RNA assay will be carried out if the antibody assay is 
positive and will determine if a HCV antibody assay is a true positiv e. 
Pregnancy Test  
For female subjects of child  bearing potential only. Pregnancy Test: WOCBP prior to dosing nivolumab. 
A serum or urine pregnancy testing is required within 24 hrs of study [treatment] enrollment or 
randomization, then every 6 weeks. [more  frequently if required by local standard]. After discontinuation 
from nivolumab these should be repeated at approximately 30 days and approximately 70 days [or more 
frequently if required by local standard] . Pregnancy tests prior to dosing must be negativ e. 
Protocol S16 -00098  Confidential  Page 49 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Immunogenicity Testing  
Blood will be collected for immunogenicity testing. Sample preparation and storage instructions are 
provided in Appendix 4.  
Immune Safety Assays  
Blood samples for measurement of immune safety parameters will be taken at the times indicated on the 
Time and Events Schedule (Table 1), and the following parameters will be measured:  
 Rheumatoid Factor   Adrenocorticotropic hormone  
 Thyroid Stimulating Hormone   C-Reactive Protein  
 Free T4 level1  Antinuclear Antibody  
1 If abnormal, the sample should be analyzed for free T3 and free T4  
The following tests may also be performed on selected stored samples .  Samples will be stored up to 10 
years   
 anti-DNA antibody   anti-neutrophil cytoplasm antibody  
 anti-phospholipid antibody   anti-thyroglobulin antibody  
 anti-thyroid receptor antibodies   anti-thyroid peroxidase  
 anti-islet cell antibody   
Additional tests and repeat tests to evaluate abnormal endocrine results may be obtained at the 
Investigator’s discretion if deemed clinically  significant. This may include follow up with prolactin and 
a.m. cortisol tests, and may require an endocrine consult.  
All research samples will be labeled with a unique code.  The PI and research staff will have access to the 
linking key.  All research sa mples will be stored for up to 10 years at NYU Langone Medical Center – 
1310 Smillow.  All research samples will be stored only for research related to this protocol.  Genetic 
tests will be performed only related to the subject’s cancer and potential use o f Nivolumab and 
Ipilumumab and will not be used to predict an individual’s risk for developing disease or passing it ot 
their children.  Subjects will not receive results of this testing.  
5.1.7.  Electrocardiogram  
A 12 -lead ECG will be performed. The subject shoul d be relaxed and should be in a resting position at 
least 5 minutes before recording the ECG. The ECGs will be reviewed by the Investigator (paper or 
electronic tracing) and will be available for comparison with subsequent ECGs by the Investigator. A 
copy of the ECG tracing must be available in the subject’s medical record for review and monitoring. The 
following will be recorded:  
 PR interval (msec)  
 QRS duration (msec)  
 QT interval (msec)  
Protocol S16 -00098  Confidential  Page 50 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  Heart rate (BPM)  
 P axes  
 R axes  
 T axes  
The clinical interpretation (normal, abnormal not clinically significant, or abnormal, clinically significant) 
will also be recorded. Any ECG finding that is judged by the Investigator as a clinically significant 
change (worsening) compared to a baseline value will be considered an a dverse event, recorded and 
monitored as described in Section  9. 
5.2. Chest Radiograph  
The Screening chest radiograph may be substituted with a chest radiograph that had been performed as 
part of the subject’s previous routine care in the 3 months prior to the i nitiation of Screening testing. 
There should be no evidence of significant abnormalities or clinical pulmonary signs or symptoms on the 
Screening physical examination. The chest radiograph report must be available in the subject’s medical 
records for revie w and monitoring.  
The clinical interpretation (normal, abnormal not related to malignant disease, or abnormal, related to 
malignant disease) will be recorded. Any finding on a repeat chest radiograph that is judged by the 
Investigator as a clinically signi ficant change (worsening) compared to a baseline value will be 
considered an adverse event, recorded and monitored as described in Section  9. 
5.3. Immunology  
Evaluations of immunology assessments (below) are summarized in Appendix 4.  
 Flow cytometry : Parameter s include but may not be limited to the following:  
 Blood and peripheral blood mononuclear cell samples will be collected and evaluated by 
leukapheresis or peripheral blood draw for flow cytometry (T cell, B cell, NK, monocytes, 
CD3, CD4, CD8, CD4/CD8, CD11 b, CD11c, CD14, CD20, CD25, CD33, CD56, CD69, 
CD71, CD73, CD80, CD127, FOXp3,  LAG3, TIGIT, BTLA, Tim3, CTLA -4, PD -1, PD -
L1, CD244, OX -40, 41 -BB, CD40, CD4/MHC Class II positive cells, and CD8/MHC Class 
II positive cells), serum cytokines (IL -6, IL -10, TNF -β, ING -gamma, TGF -β, neopterin and 
sIL-2R), cellular immune function (tetramer and/or ELIspot assays utilizing melanoma and 
other control antigens).  
 Percent and absolute CD4 and CD8 counts and CD4/CD8 ratio  
 Two color analyses to determine percent and abso lute numbers for: CD4/MHC Class II 
positive cells  
 Two color analyses to determine percent and absolute numbers of: CD8/MHC Class II 
positive cells  
Protocol S16 -00098  Confidential  Page 51 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  Serum samples will be collected and cryopreserved to study molecules that may be 
implicated in regulating ant i-melanoma immune responses and/or NIVOLUMAB or 
ipilimumab activity such as soluble MICA, compounds detected by mass spectroscopy 
including those associated with wound healing, complement and the acute phase response, 
chemokines or cytokines, or antibodies  to melanoma antigens.   
 Cellular Immune Function Assays that may include, but will not be limited to proliferation and/or 
ELIspot assays utilizing melanoma and other control antigens (Appendix 4). 
 Serum samples will be collected and cryopreserved to study molecules that may be identified based 
on prior analyses of acute phase reactants  and may be implicated in regulating anti -melanoma 
immune responses and/or NIVO LUMAB with ipilimumab activity.  
5.4. Effic acy 
Using imaging results (ie, computed tomography/magnetic resonance imaging of the chest, abdomen, 
pelvis, and brain; and photography of lesions), efficacy defined as relapse free survival will be evaluated 
and treatment decisions will be made by the Inv estigator. CT of the neck will be performed in patients 
with prior disease of the head and neck.  
At the Sponsor -investigator ’s discretion, scans and measurements may be reviewed by independent 
radiologists using irRC and/or standard RECIST 1.1 criteria at  a later date or any time during the study.  
Because immunotherapy may cause a delayed onset of tumor response, there will be cases that warrant 
confirmation of progressive disease (eg,  borderline progression, apparent radiologic progression with 
improving  clinical status).  
Only subjects without relapse will receive additional doses of the study drugs, until confirmed relapse, 
development of a DLT, or other intolerability to therapy . Subjects with a confirmed relapse will not 
receive additional doses, and will complete all of the remaining evaluations without dosing. Subjects who 
discontinue treatment with the study drugs prematurely will complete the remaining visits and 
assessments except for the study drug infusions and pharmacokinetic sample collection,  which will only 
be done at the visit following discontinuation of the study drugs.  
Imaging will be performed as outlined in Table 1 and Appendix 1.  
 
5.5. Subject Completion/Early Discontinuation  
It will be documented whether or not each subject completed the T reatment and the Treatment/Follow -up 
Period, how long they followed, and the reason for withdrawal from the study.  
Protocol S16 -00098  Confidential  Page 52 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 5.6. Research Specimen Procedures  
5.6.1.  Tumor Tissue Specimens  
If available, p re-treatment tumor tissue specimens in the form of a paraffin embedded blo ck or a 
minimum of 10 unstained slides from the most recent tumor resection or biopsy will be submitted for 
central PD -L1 immunohistochemistry (IHC) assessment , and determination of other tumor 
microenvironment biomarkers such as CD8 T cell infiltrate and other biomarkers by IHC based on 
emerging science . In addition, patients will be asked to consent to have any post -relapse specimens 
previously resected as standard of care analyzed in a similar manner by immunohistochemistry. These 
biopsy samples should b e excisional, incisional, punch or core needle. Fine needle aspirates or other 
cytology specimens are insufficient for downstream biomarker analyses. PD -L1 stained tissue sections 
will be assessed by a pathologist and scored as PD -L1 positive if membrane s taining is observed in >5% 
tumor cells among a minimum of a hundred (100) evaluable tumor cells. Samples with < 5% tumor cell 
membrane staining in a minimum of a hundred (100) evaluable tumor cells will be scored as PD -L1 
negative and samples where membran e staining is obscured by high cytoplasm ic staining or melanin 
content, but contain the minimum number of evaluable tumor cells will be deemed PD -L1 indeterminate.  
 
5.6.2.  Research Blood Samples  
Research blood samples will be taken at timepoints outlined in Tabl e 1.  Refer to Appendix 4 for specific 
processing and handling procedures for research blood specimens.  All subjects will have blood samples 
collected.   
5.6.3.  Analysis of Immunological Response   
For each time point (at baseline and Weeks 7 and 13) the percent  of subjects with a response will be 
calculated – for T -cell proliferation response, along with an exact confidence interval.  
Cryopreserved Serum  
Serum samples will be analyzed to evaluate molecules that may be identified and implicated in regulating 
anti-melanoma immune responses and/or NIVOLUMAB/ipilimumab activity such as soluble MICA, and 
antibodies to melanoma antigens  
6. STATISTICAL PLAN  
6.1. Sample Size Determination  
The sample size of up to approximately 25 subjects (total of 20 including screening failure s and drop -
outs) is based on the study design for safety and immune assays.  
6.2. Study Population  
The subject populations are defined below.  
6.2.1.  Safety Population  
The Safety Population includes all subjects in the study who received at least 1 dose or any partial dose of 
NIVOLUMAB and/or ipilimumab . 
Protocol S16 -00098  Confidential  Page 53 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 6.2.2.  Evaluable Population  
The Evaluable Population includes subjects in the Safety Population who have the correct disease 
diagnosis, do not have any major protocol or inclusion/exclusion violations, have no major dosing 
violations, and who have a valid baseline and at least one post -baseline tumor assessment.  
6.3. Statistical Analysis  
The data collected in this study will be analy zed by the Biostatistics group at the Perlmutter Cancer 
Center at NYU . 
All data will be listed individually by subject. For quantitative parameters, descriptive statistics will 
include the mean, standard deviation, minimum, median, and maximum. For qualitative parameters, 
descriptive statistics will include frequency and percentage.  
Unless otherwise indicated, the statistical significance will be declared if the two -sided p -value is  0.05.  
6.3.1.  Demographics and Baseline Characteristics  
Subject demographi cs and baseline characteristics including age, sex, race, height, weight, tumor 
information, medical conditions, etc. will be summarized using descriptive statistics  
6.3.2.  Concomitant Medication  
Concomitant medications and significant non -drug therapies will be summarized using descriptive 
statistics.  
6.3.3.  Safety  
The safety analysis will be conducted on the Safety Population. The following safety parameters will be 
evaluated: adverse events, clinical laboratory tests, physical examinations, vital signs, ECOG 
performa nce status, ECGs, chest radiographs, immune safety, and immunogenicity. All safety parameters 
will be summarized using descriptive statistics.  
 Adverse Events  
Treatment -emergent adverse events (TEAEs) are defined as signs or symptoms that emerge during 
treatment or within 100 days of the last dose of study drug, including those signs and symptoms 
that have been absent pre -treatment or that have worsened relative to the pre -treatment assessment. 
Any adverse event considered related to treatment will also be c onsidered a treatment -emergent 
adverse event (TEAE), regardless of the elapsed time since the last dose of study drug.  
An irAE, a subset of adverse events, is defined as a clinically significant adverse event of any organ 
that is associated with study drug  exposure, of unknown etiology, and is consistent with an 
immune -mediated mechanism.  
All adverse events recorded during the study will be summarized using descriptive statistics. The 
incidence of TEAEs will be summarized by body system, preferred term, verbatim of adverse 
event, intensity (based on CTCAE Version 4.0 grade), and relationshi p to each study drug 
(NIVOLUMAB and/or the ipilimumab).  
Protocol S16 -00098  Confidential  Page 54 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  Vital Signs  
The observed vital signs at each visit and the change from baseline to each post -baseline visit will 
be summarized by cohort using descriptive statistics.  
 Physical Examination  
Abnormal fin dings in physical examination will be summarized using descriptive statistics.  
 Clinical Laboratory Tests  
Clinical laboratory test values outside the normal range and clinically significant abnormal range 
will be flagged in the data listing.  
Laboratory data  will be summarized using shift tables (baseline to notable post -baseline visit). The 
change from baseline will be summarized using descriptive statistics.  
 ECOG  
The data observed from ECOG performance status will be summarized appropriately .  
 Other Safety Evaluations  
The results of ECGs, chest radiographs, immune safety tests, and immunogenicity will be summarized 
appropriately.  
6.3.4.  Immunology Parameters  
The data from each of the assays and assessments described in Appendix 4 will be summarized by week 
of stud y, using standard descriptive statistical methods – preferably parametric if the distribution of the 
continuous assay data (possibly after transformation) is compatible with the assumptions of a normal 
distribution, and non -parametric otherwise. For each i mmunological marker studied, one of the following 
4 transformations will be used: identity (ie, no transformation), square -root, cube root, or log 
transformation. Choice of the transformation will be made by computing the Anderson -Darling statistic 
based o n the regression model residues using the pooled data. Then the transformation with the lowest 
Anderson -Darling statistic will be selected as the most normal -like and used in the mixed model analysis.  
Scatterplots of the data for the individual subjects, over time, will be constructed to display the patterns; 
means (or geometric means or medians) with confidence intervals will also be plotted; contingency tables 
will be used for the categorical assay responses.   For baseline and weeks 7 and 13, regression  methods 
(linear or logistic) that accommodate random effects will be used to evaluate the effect of the treatment 
regimen  on the overall levels and on the trends over time – with subject as the random effect and week as 
the fixed effects. These analyses w ill be used to evaluate the quantitative effects of the NIVOLUMAB + 
ipilimumab regimen  on immunologic and pharmacodynamic changes due to treatment. While formally 
proving that the addition of NIVOLUMAB to ipilimumab will increase the probability of clinica l benefit 
is beyond the scope of this trial, the data obtained will be used to test the hypothesis that the magnitude of 
the proliferating T -cells (as continuous) will increase with NIVOLUMAB added to ipilimumab compared 
to the prior cohorts of protocol 15 651 at Moffitt Cancer Center with NIVOLUMAB alone. Note that the 
pre and post treatment assays from any given subject that are used in the analysis are always performed 
on the same plate, thus eliminating a potential confounding factor due to plate -to-plate assay variation.  
Protocol S16 -00098  Confidential  Page 55 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Due to the exploratory nature of this trial, there will be no formal adjustments made to account for the 
multiple statistical testing performed on the 11 surface and intracellular biomarkers under investigation. 
However, to guard against  having a possibly over -inflated overall type I error rate, result sensitivity will 
be high if 3 or more phenotypic changes occur with addition of ipilimumab at an individual  level of 
0.05 each for further studying these phenotypic changes in NIVOLUMAB + ipilimumab treated cells. In 
the case of doing 11 independent hypothesis testings with an  level of 0.05 each, the probability of 
having 3 or more significant results by chan ce will be only about 0.015, whereas, the probability of 
having at least 1 or 2 significant results is 0.43 or 0.10, respectively  
In addition to analyzing the results of these assays as continuous variables, the T -cell proliferation  assay 
results will be c lassified as “response” or “non -response” to further explore the relationship of 
immunologic changes with treatment . 
6.3.4.1.  T-cell Proliferation  
The definition of augmented proliferation for the purposes of this trial will be a 20% increase, at Week 
12, in the ab solute proportion of CD107a positive CD8+ T cells that stain with the Ki -67 marker.  
6.4. Missing Data Handling  
Unresolved missing data may be imputed when the analysis integrity is affected. The conservative 
principle will be used for data imputation. For examp le, if an adverse event onset day is missing but the 
adverse event onset year and month cannot exclude this adverse event as a TEAE, the adverse event will 
be flagged as a TEAE.  
6.5. Statistical Software  
All statistical analyses will be performed using SAS Version 8.2 or higher.  
SAFETY AND ADVERSE EVENT REPORT ING  
6.6. Definitions  
An Adverse Event (AE)  is defined as any new untoward medical occurrence or worsening of a pre -
existing medical condition in a patient or clinical investigation subject administered an i nvestigational 
(medicinal) product and that does not necessarily have a causal relationship with this treatment. An AE 
can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for 
example), symptom, or disease tempora lly associated with the use of investigational product, whether or 
not considered related to the investigational product.  A laboratory abnormality is considered an adverse 
event if it results in discontinuation from the study drugs, necessitates therapeuti c medical intervention, or 
if the Investigator assesses the abnormality as an adverse event.  
6.7. Serious Adverse Events  
A serious adverse event (SAE)  is any untoward medical occurrence that:  
 results in death  
Protocol S16 -00098  Confidential  Page 56 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  is life -threatening (defined as an event in which t he subject was at risk of death at the time of the 
event; it does not refer to an event that hypothetically might have caused death if it were more severe)  
 requires inpatient hospitalization or causes prolongation of existing hospitalization (see “note” be low 
for exceptions)  
 results in persistent or significant disability/incapacity  
 is a congenital anomaly/birth defect  
 Suspected transmission of an infectious agent (eg, any organism, virus or infectious particle, 
pathogenic or non -pathogenic) via the study drug is an SAE.  
 is an important medical event (defined as a medical event(s) that may not  be immediately life -
threatening or result in death or hospitalization but, based upon appropriate medical and scientific 
judgment, may jeopardize the subject or may r equire intervention [eg, medical, surgical] to prevent 
one of the other serious outcomes listed in the definition above.) Examples of such events include, but 
are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm ; 
blood dyscrasias or convulsions that do not result in hospitalization.)  
 Although overdose and cancer are not always serious by regulatory definition, these events should be 
reported on an SAE form and sent to BMS in an expedited manner. An overdose is de fined as the 
accidental or intentional ingestion or infusion of any dose of a product that is considered both 
excessive and medically important.  
NOTE: The following hospitalizations are not considered SAEs in BMS clinical studies:  
 a visit to the emergency room or other hospital department for less than 24  hours that does not result 
in admission (unless considered an “important medical event” or a life -threatening event)  
 elective surgery, planned before signing consent  
 admissions as per protocol for a planne d medical/surgical procedure  
 routine health assessment requiring admission for baseline/trending of health status (eg, routine 
colonoscopy)  
 medical/surgical admission for purpose other than remedying ill health state and was planned prior to 
entry into the  study. Appropriate documentation is required in these cases  
 admission encountered for another life circumstance that carries no bearing on health status and 
requires no medical/surgical intervention (eg, lack of housing, economic inadequacy, care -giver 
respite, family circumstances, administrative).  
Note that all pregnancies, regardless of outcome, must be reported to the sponsor -investigator  on a 
Pregnancy Surveillance Form, not an SAE form. All pregnancies must be reported and followed to 
outcome, includ ing pregnancies that occur in the female partner of a male study subject.  See Section 8. 4 
for instructions on reporting pregnancies.  
 
Nonserious Adverse Events  
A non-serious adverse event  is an AE not classified as serious.  
6.7.1.  Assignment of Adverse Event Intensity and Relationship to Investigational Product  
Describe how adverse events (AEs and SAEs) will be graded, for example:  
For oncology studies:  
Protocol S16 -00098  Confidential  Page 57 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Version 4.0 of the NCI Common Terminology Criteria for Adverse Events (CTCAE) will be utilized for 
AE reporting.   Version 4.0 of the CTCAE is identified and located on the CTEP website at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm .  All appropriate treatment 
areas should have access to a copy of Version 4.0 of CTCAE.  
The following categories and definitions of causal relationship to investigational product as determined 
by a physician should be used:  
 Related:  There is a reasonable causal relationship to investigational product administration and the 
adverse e vent.  
 Not Related:  There is not a reasonable causal relationship to investigational product administration 
and the adverse event.  
The expression “reasonable causal relationship” is meant to convey in general that there are facts (eg, 
evidence such as de -challenge/re -challenge) or other arguments to suggest a positive causal relationship.  
6.7.2.  Collection and Reporting  
Adverse events can be spontaneously reported or elicited during open -ended questioning, examination, or 
evaluation of a subject. (In order to preve nt reporting bias, subjects should not be questioned regarding 
the specific occurrence of one or more AEs.)  
If known, the diagnosis of the underlying illness or disorder should be recorded, rather than its individual 
symptoms. The following information sho uld be captured for all AEs: onset, duration, intensity, 
seriousness, relationship to investigational product, action taken, and treatment required. If treatment for 
the AE was administered, it should be recorded in the medical record.  
The sponsor -investig ator shall supply th e ethics Committee with any additional requested information, 
notably for reported deaths of subjects . 
6.8. Reporting of Serious Adverse Events and Unanticipated Problems  
Following the subject’s written consent to participate in the study, all SAEs, whether related or not related 
to study drug, must be collected, including those thought to be associated with protocol -specified 
procedures. All SAEs must be collected that occ ur within 100 days of discontinuation of dosing.  CTCAE 
version 4.03 terms should be used.   
The collection of nonserious AE information should begin at initiation of study drug. All nonserious 
adverse events (not only those deemed to be treatment -related)  should be collected continuously during 
the treatment period and for a minimum of 100 days following the last dose of study treatment. 
Additionally, any SAE or other AE of concern that the investigator believes may be related to study 
treatment and that o ccurs later than 30 days after last study treatment should be reported. Information for 
any non -serious AE that starts during the treatment period or within 70 days after last treatment will be 
collected from the time of the event until resolution of the e vent, or until the patient’s last study visit, 
whichever comes first. Serious adverse event information will be collected until the event is considered 
chronic and/or stable.   
 
All fatal or life -threatening adverse events must be immediately reported to t he Sponsor -investigator  by 
telephone or e -mail. Within 24 hours of the event, the Serious Adverse Event (SAE) Form supplied by 
NYULMC must be faxed to the Sponsor -investigator and BMS , who must then inform the NYULMC 
IRB, PCC CTO, and DSMC within 24 hours of the event whether full information regarding the event is 
Protocol S16 -00098  Confidential  Page 58 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 known or not. Additional follow -up by the investigator will be required if complete information is not 
known. De -identified source documentation of all examinations, diagnostic procedures, etc. w hich were 
completed with respect to the event should be included with the SAE form. Care should be taken to 
ensure that the patient’s identity is protected and the patient’s identifiers (as assigned at the time of study 
enrollment) are properly mentioned o n any copy of source document provided to the Sponsor -
investigator . For laboratory results, include the laboratory normal ranges.  
 
In case of accidental or intentional overdose of study drug, even if asymptomatic or not fulfilling a 
seriousness criterion, the overdose is to be reported to the Sponsor -investigator  and BMS immediately 
(within 1 working day) using the AE and SAE forms supplied by NYULMC. Overdose of study drug will 
be defined as at least 2 times the intended dose of study drug within the inten ded therapeutic window.  
 
All serious adverse events (SAEs) will be evaluated by the DSMC If meeting the requirements for 
expedited reporting, the Sponsor -investigator  will report the adverse event to all regulatory authorities 
with jurisdiction over ongoin g trials with the study drug and to all other investigators involved in clinical 
trials with the study drug. The investigator is responsible for reporting all SAEs to the appropriate IRB, 
DSMC, Sponsor -investigator, BMS  and FDA . 
6.8.1.  Investigator reporting:  no tifying the IRB  
 
Federal regulations require timely reporting by investigators to their local IRB of unanticipated problems 
posing risks to subjects or others . The IRB requirements reflect the current guidance documents released 
by the Office of Human Research Protection (OHRP), and the Food and Drug Administration (FDA) and 
are respectively entitled “Guidance on Reviewing and Reporting Unanticipated Problems I nvolving Risks 
to Subjects or Others and Adverse Events”  and “Guidance for Clinical Investigators, Sponsors, and IRBs:  
Adverse Event Reporting -Improving Human Subject Protection.”   The following describes the 
NYULMC IRB reporting requirements, though In vestigators at participating sites are responsible for 
meeting the specific requirements of their IRB of record. The NYU IRB address is:  
 
NYULMC IRB  
1 Park Avenue, 6th Floor  
New York, NY 10016  
6.8.2.  Serious Adverse Events  
The following information is provided t o investigators for either inclusion in protocol documents or other 
related study documents. It will also be contained in the Study Agreement:  
Following the subject’s written consent to participate in the study, all SAEs must be collected, including 
those thought to be associated with protocol -specified procedures. All SAEs must be collected that occur 
within 100 days of discontinuation  of dosing of the investigational product. If applicable, SAEs must be 
collected that relate to any later protocol -specifie d procedure (eg, a follow -up skin biopsy). The 
investigator should notify BMS of any SAE occurring after this time period that is believed to be 
certainly, probably, or possibly related to the investigational product or protocol -specified procedure.  
All SA Es should be followed to resolution or stabilization.  
Protocol S16 -00098  Confidential  Page 59 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 The Sponsor/Investigator will ensure that all SAEs in the clinical database are reported to BMS and any 
applicable health authority during the conduct of the study. This reconciliation will occur at lea st 
quarterly and be initiated by the sponsor/investigator. Sponsor/investigator will request a reconciliation 
report from: aepbusinessprocess@bms.com . During reconciliation, any events found to not be repor ted 
previously to BMS must be sent to Worldwide.Safety@BMS.com . 
All SAEs should be faxed or emailed to BMS at:  
Global Pharmacovigilance & Epidemiology  
Bristol -Myers Squibb Company  
Fax Number: 609 -818-3804  
Email: Worldwide.safety@bms.com  
For studies conducted under an Investigator IND , any suspected adverse event that is both serious and 
unexpected must be reported to the FDA as soon as possible and, in no event, later than 7 days (death or 
life-threatening event) or 15 days (all other SAEs) after the investigator’s or institution’s initial receipt of 
the information. BMS will be provided with a simultaneous copy of all adverse events filed with the 
FDA. SAEs should be reported on the MedWatch Form 3500A, whi ch can be accessed at:  
http://www.accessdata.fda.gov/scripts/medwatch/.  
MedWatch SAE forms should be sent to the FDA at:  
MEDWATCH  
5600 Fishers Lane  
Rockville, MD 20852 -9787  
Fax: 1 -800-FDA -0178 (1 -800-332-0178)  
http://www.accessdata.fda.gov/scripts/medwatch/  
All SAEs should simultaneously be faxed or e -mailed to BMS at:  
Global Pharmacovigilance & Epidemiology  
Bristol -Myers Squibb Company  
Fax Number: 609 -818-3804  
Email: Worldwide.safety@bms.com  
The  contact information for submitting IND safety reports is noted below:  
 Email:  NYUPCCsafety@nyumc.org  
 Tel:  212 -263-4427  
 
Serious adverse events, whether related or unrelated to investigational product, must be recorded on the 
SAE page and reported expeditiously to BMS (or designee) to comply with regulatory requirements. An 
SAE report should be completed for any event where doubt exists regarding its status of seriousness .  
All SAEs must be immediately reported by confirmed facsimile transmission (fax) and mailing of the 
completed SAE page. In some instances where a facsimile machine is not available, overnight express 
mail may be used. If only limited information is initially available, follow -up reports are required. (Note: 
Follow -up SAE reports should include the same investigator term(s) initially reported.) In selected 
circumstances, the protocol may specify conditions that require additional telephone reporting.  
Protocol S16 -00098  Confidential  Page 60 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 If the in vestigator believes that an SAE is not related to the investigational product, but is potentially 
related to the conditions of the study (such as withdrawal of previous therapy, or a complication of a 
study procedure), the relationship should be specified in the narrative section of the SAE page.  
If an ongoing SAE changes in its intensity or relationship to the investigational product, a follow -up SAE 
report should be sent immediately to the Sponsor --investigator . As follow -up information becomes 
available it should be sent immediately using the same procedure used for transmitting the initial SAE 
report. All SAEs should be followed to resolution or stabilization.  
6.8.3.  Handling of Expedited Safety Reports  
In accordance with local regulations, BMS will notify inve stigators of all SAEs that are suspected 
(certainly, probably, or possibly related to the investigational product) and unexpected (ie, not previously 
described in the Investigator Brochure). In the European Union (EU), an event meeting these criteria is 
termed a Suspected, Unexpected Serious Adverse Reaction (SUSAR). Investigator notification of these 
events will be in the form of an expedited safety report (ESR).  
Other important findings which may be reported by the sponsor -investigator  as an ESR include:  increased 
frequency of a clinically significant expected SAE, an SAE considered associated with study procedures 
that could modify the conduct of the study, lack of efficacy that poses significant hazard to study subjects, 
clinically significant safety fi nding from a nonclinical (eg, animal) study, important safety 
recommendations from a study data monitoring committee, or sponsor -investigator  decision to end or 
temporarily halt a clinical study for safety reasons.  
Upon receiving an ESR from BMS, the inves tigator must review and retain the ESR with the Investigator 
Brochure. Where required by local regulations or when there is a central IRB/IEC for the study, the 
sponsor -investigator  will submit the ESR to the appropriate IRB/IEC. The investigator and IRB/I EC will 
determine if the informed consent requires revision. The investigator should also comply with the 
IRB/IEC procedures for reporting any other safety information.  
In addition, suspected serious adverse reactions (whether expected or unexpected) shal l be reported by 
BMS to the relevant competent health authorities in all concerned countries according to local regulations 
(either as expedited and/or in aggregate reports).  
6.8.3.1.   Non-serious Adverse Events  
The collection of nonserious AE information should be gin at initiation of investigational product. 
Nonserious AE information should also be collected from the start of a placebo lead -in period or other 
observational period intended to establish a baseline status for the subjects.  
If an ongoing non -serious AE worsens in its intensity, or if its relationship to the investigational product 
changes, a new non -serious AE entry for the event should be completed. Non -serious AEs should be 
followed to resol ution or stabilization, or reported as SAEs if they become serious. Follow -up is also 
required for non -serious AEs that cause interruption or discontinuation of investigational product, or those 
that are present at the end of study participation. Subjects with non -serious AEs at study completion 
should receive post -treatment follow -up as appropriate.  
Protocol S16 -00098  Confidential  Page 61 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 All identified non -serious AEs must be recorded and described in the medical record.  
6.9. Pregnancy  
Sexually active WOCBP must use an effective method of birth control during the course of the study, in a 
manner such that risk of failure is minimized. Before enrolling WOCBP in this clinical study, the 
investigator must review the guideline about study participation for WOCBP which can be found in the 
GCP Manual f or Investigators. The topics include the following:  
 General Information  
 Informed Consent Form  
 Pregnancy Prevention Information Sheet  
 Drug Interactions with Hormonal Contraceptives  
 Contraceptives in Current Use  
 Guidelines for the Follow -up of a Reported Pre gnancy.  
Before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study 
participation and the potential risk factors for an unintentional pregnancy. The subject must sign an 
informed consent form documenting this discuss ion. 
All WOCBP MUST have a negative pregnancy test within 72  hours before receiving 
NIVOLUMAB . The minimum sensitivity of the pregnancy test must be 25 IU/L or equivalent units of 
HCG. If the pregnancy test is positive, the subject must not receive NIVOLUM AB and must not be 
enrolled in the study.  
In addition, all WOCBP should be instructed to contact the investigator immediately if they suspect 
they might be pregnant (e.g., missed or late menstrual period) at any time during study 
participation.  
If, following initiation of the investigational product, it is subsequently discovered that a study subject is 
pregnant or may have been pregnant at the time of investigational product exposure, including during at 
least 6 half -lives after product administrati on, the investigational product will be permanently 
discontinued in an appropriate manner (eg, dose tapering if necessary for subject safety). The investigator 
must immediately notify BMS of this event and record the pregnancy on the Pregnancy Surveillance  
Form (not an SAE form). Initial information on a pregnancy must be reported immediately to BMS, and 
the outcome information provided once the outcome is known. Completed Pregnancy Surveillance Forms 
must be forwarded to BMS according to SAE reporting proc edures.  
Any pregnancy that occurs in a female partner of a male study participant should be reported to the 
Sponsor -investigator . Information on this pregnancy will be collected on the Pregnancy Surveillance 
Form.  
Protocol -required procedures for study dis continuation and follow -up must be performed on the subject 
unless contraindicated by pregnancy (e.g., x -ray studies). Other appropriate pregnancy follow -up 
procedures should be considered if indicated. In addition, the investigator must report to BMS,  NYU LMC  
Protocol S16 -00098  Confidential  Page 62 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 PCC, and follow -up on information regarding the course of the pregnancy, including perinatal and 
neonatal outcome. Infants should be followed for a minimum of 8  weeks.  
6.9.1.  Follow -up 
For female subjects, protocol -required procedures for study discontinuatio n and follow -up must be 
performed (Section 8) unless contraindicated by pregnancy (eg, radiograph studies). Other appropriate 
pregnancy follow -up procedures should be considered if indicated. Follow -up information regarding the 
course of the pregnancy, inc luding perinatal and neonatal outcome should be reported where possible.  
For male subjects, follow -up information regarding the course of the partner’s pregnancy, including 
perinatal and neonatal outcome, should be reported where possible.  
Infants should b e followed for a minimum of 8 weeks and the outcome reported where possible.  
6.10. Immune -related Adverse Events  
An irAE, a subset of adverse events, is defined as a clinically significant adverse event of any organ that 
is associated with study drug exposure, o f unknown etiology, and is consistent with an immune -mediated 
mechanism. Appropriate efforts should be made to rule out neoplastic, infectious, metabolic, toxin, or 
other etiologic causes of the irAE.  
Given the intended mechanism of action of NIVOLUMAB  and/or ipilimumab, namely disinhibition of 
cellular immune responses, it is possible that syndromes may develop that are most consistent with an 
underlying enhanced immune response as the driving factor. Such events may consist of persistent rash, 
diarrhea an d colitis, autoimmune hepatitis, arthritis, glomerulonephritis, or cardiomyopathy. The 
spectrum of irAEs is currently hypothetical, as very few human subjects have been treated to date, and are 
based upon preclinical studies in mice deficient in PD -1, as w ell as experience with other monoclonal 
antibodies that act by disinhibiting the immune response. Such irAEs may resolve with time, or may 
require institution of counteracting immunosuppressive therapies.  
BMS has observed irAEs in another development progr am with the immunostimulatory antibody, 
ipilimumab (anti -CTLA -4). Ipilimumab -induced irAEs are typically low grade and self limited, more 
often occur after multiple doses, and most frequently involve the gastrointestinal tract (diarrhea/colitis), 
skin (ras hes), liver (hepatitis), and endocrine systems (a variety of endocrinopathies). In addition, the 
known animal and human toxicity profiles of anti -CTLA -4 antibodies such as ipilimumab include colitis 
as an expected adverse event. Based on these consideratio ns, NIVOLUMAB  may also cause immune -
mediated colitis.  Uveitis and visual changes may also be seen.   
Colitis is characterized by new onset of diarrhea, which may be accompanied by abdominal pain and or 
gastrointestinal bleeding. Events of Grade 3 or Grade  4 diarrhea as well as Grade  2 diarrhea with blood in 
stool should be eva luated for colitis. All adverse events of colitis > Grade 2 are deemed to be of special 
interest, and should be reported to BMS within 24  hours of occurrence using the serious adverse  event 
reporting procedures (Described in Section 8.3), even if the adverse event itself is not deemed as serious.  
Protocol S16 -00098  Confidential  Page 63 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Management Algorithms for High Grade irAEs  
Management algorithms for high -grade irAEs have been established for ipilimumab, where timely 
application of defined immunosuppressive regimens appear to be effective in limiting the morbidity and 
mortality from such events without compromising therapeutic efficacy. A general management algorithm 
with recommended guidelines for the treatment and monito ring of suspected irAEs, as well as algorithms 
for specific irAEs (ie, diarrhea/colitis, endocrinopathy, hepatotoxicity, and neuropathy) are provided in 
the NIVOLUMAB  Investigator Brochure. All incidents of diarrhea should be managed according to 
the diarr hea/colitis algorithm. Additional clinical experience will be required to define the spectrum of 
irAE -like events that may emerge in the NIVOLUMAB  program, and these algorithms are useful guides 
towards establishing an effective management approach as expe rience accumulates.  
In all cases, study drug -related  Grade 2 diarrhea/colitis will be managed with regular communication 
between the Investigator and BMS, and with a minimum of at least 1 in -person visit per week until the 
diarrhea/colitis is < Grade 2. Any Grade  2 adverse event of colitis (per Version 4.0 CTCAE) that also 
results in additional medical requirements, such as more than 2 weeks of immunosuppressive doses of 
steroids (> 10 mg/day of prednisone or equivalent), blood transfusion, or i.v. hypera limentation, will be 
defined as a Grade 3 adverse event. Subjects are to be carefully monitored until recovery of the colitis to 
≤ Grade 1.  
6.11. Rapid Notification of Adverse Events of Special Interest  
In addition to serious adverse events, overdose, and pregnancy, the following adverse events will also be 
reported on an expedited basis to the designated email address:  Worldwide.safety@bms.com  
 Adverse events that potentially meet DLT criteria;  
  Grade 2 study -drug related adverse events (including neurologic toxicity);  
 Grade 3 or 4 infusion reactions;  
  Grade 2 diarrhea/colitis;  
  Grade 3 irAE other than diarrhea/colitis;  
  Grade 4 study drug -related h epatic failure; and  
  Grade 3 motor neurologic toxicity regardless of causality  
6.12. Medical Monitoring  
It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her site.  This 
safety monitoring will include careful ass essment and appropriate reporting of adverse events as noted 
above, as well as the construction and implementation of a site data and safety -monitoring plan.  Adverse 
events are evaluated monthly by the principal investigator in conjunction with the resear ch team.  The 
Data Safety and Monitoring Committee (DSMC) will review the study twice a year.  Medical monitoring 
will include a regular assessment of the number and type of serious adverse events.  
 
Protocol S16 -00098  Confidential  Page 64 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 6.12.1.  Data and Safety Monitoring Committee  
This investigator -initiated study will be monitored by the Data Safety Monitoring Committee (DSMC) of 
the New York University (NYU) Perlmutter Cancer Center (PCC). The DSMC operates based on the 
2011 National Cancer Institute approved Charter.  It is an existing and multidisc iplinary committee 
(consisting of clinical investigators/oncologists, biostatisticians, nurses, and research administration staff 
knowledgeable of research meth odology and design and in proper conduct of clinical trials) that is 
responsible for monitoring safety, conduct and compliance in accordance with protocol data monitoring 
plans for clinical trials conducted in the NYULMC Perlmutter Cancer Center that are not monitored by 
another institution or agency. The DSMC reports to the Director of the NYULMC PC C.  Per the NYU 
PCC Institutional Data Safety and Monitoring Plan, this trial will be monitored by DSMC twice annually 
(from the date the first patient is enrolled),  subsequent cohort activation, and at the completion of the 
study prior to study closure. T his review includes accrual data, subject demographics and adverse events.   
Principal Investigators are required to attend the review of their studies. Additional reviews can be 
scheduled based on SAE reports, investigator identified issues, external information, etc. The DSMC will 
review safety data every 6 -8 weeks. . 
6.12.2.  Efficacy  
Efficacy analyses will be conducted on the Safety and Evaluable populations.  
6.13  Overdose  
An overdose is defined as the accidental or intentional administration of any dose of a product that is 
considered both excessive and medically important. All occurrences of overdose must be reported as an 
SAE.  
6.14  Other Safety Considerations  
Any significant worsening noted during interim or final physical examinations, electrocardiograms , 
x-rays, and any other potential safety assessments, whether or not these procedures are required by the 
protocol, should also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.  
 
7. DATA HANDLING AND RE CORD KEEPING  
7.1. Confidentiality Regarding Study Subjects  
Investigators must ensure that the privacy of subjects, including their personal identity and all personal 
medical information, will be protected at all times, as required by law. In CRFs and other study 
documents, subjects will be identified by their initials, subject number, date of birth, and/or gender.  
Personal medical information may be reviewed and/or copied for research, quality assurance, and/or data 
analysis. This review may be conducted by the Sponsor -inves tigator , properly authorized persons on 
behalf of the Sponsor -investigator , an independent auditor, the IRB, or regulatory authorities. Personal 
medical information will always be treated as confidential.   The study team  will maintain clinical and 
laborato ry data in a designed manner to ensure patient confidentiality.  All study personnel have passed 
human subject protection courses.  If applicable, tissue samples sent to collaborators outside of 
NYULMC will only be labeled with an assigned protocol -subject  identification number without patient 
identifiers.  Systems used for electronic data capture are compliant with HIPAA and applicable local 
Protocol S16 -00098  Confidential  Page 65 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 regulatory agency guidelines.  All documents are kept in strictly confidential files and are only made 
accessible fo r specific study personnel, CTO quality assurance specialists, and authorized representatives 
of regulatory agencies as described in the informed consent document .  The Investigator agrees to keep all 
information provided by BMS in strict confidence and to  request similar confidentiality from his/her staff 
and the IRB. Study documents provided by BMS (eg, NIVOLUMAB Investigators’ Brochure) will be 
stored appropriately to ensure their confidentiality. Such confidential information may not be disclosed to 
others without direct written authorization from BMS, Inc., except to the extent necessary to obtain 
informed consent from subjects who wish to participate in the study.  
 
7.2. Confidentiality and HIPAA  
Information about study subjects will be kept confidential and  managed according to the requirements of 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a 
signed subject authorization informing the subject of the following:  
 What protected health information (PHI) wi ll be collected from subjects in this study  
 Who will have access to that information and why  
 Who will use or disclose that information  
 The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revok es authorization to collect or use PHI, the investigator, by regulation, 
retains the ability to use all information collected prior to the revocation of subject authorization.  For 
subjects that have revoked authorization to collect or use PHI, attempts sh ould be made to obtain 
permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study 
period . 
7.3. Source Documentation  
Source data is all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in 
source documents.  Examples of these original documents, and data records include: hospital records, 
clinical and office charts , laboratory notes, memoranda, subjects’ diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified 
after verification as being accurate and complete, microfiches, microfilm o r magnetic media, x -rays, 
subject files, and records kept at the pharmacy, at the laboratories, and at medico -technical departments 
involved in the clinical trial . 
7.4. Data and Source Documentation  
Velos, an electronic database capture system will be created t o record the data for this trial.  Research 
coordinators will input clinical trial data into the database.  This database is password protected and only 
the PI, assigned research coordinator, and CTO quality assurance specialists will have access to the 
database.  Velos is the primary data collection instrument for the study.  All data requested in Velos must 
Protocol S16 -00098  Confidential  Page 66 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 be reported.  All missing data must be explained.  The quality assurance specialists will monitor this trial 
every 6 -8 weeks for data entry accuracy.  
7.5. Recording of Data and Retention of Documents  
All information required by the protocol should be recorded in source documents and CRFs; any 
omissions or corrections should be explained.  
All entries to the CRFs must be clear and must be completed in black ba ll-point pen to ensure the 
legibility of self -copying or photocopied pages. Corrections will be made by placing a single horizontal 
line through the incorrect entry, so that the original entry can still be seen, and placing the revised entry 
beside it. The  revised entry must be initialed and dated by a member of the Investigator’s research team 
authorized to make CRF entries. Correction fluid must not be used.  
The Investigator must maintain source documents for each subject in the study. All information on CRFs 
will be traceable to these source documents, which are generally maintained in the subject’s file. The 
source documents will contain all demographic and medical information (eg,  laboratory data, ECGs, 
diagnostic test results, assessment of presence or  absence of adverse events, changes in concomitant 
medications), and a copy of the signed ICF, which should indicate the study number and title of the study.  
Essential documents, as listed below, will be retained by the Investigator for as long as needed t o comply 
with national regulations.  
Essential documents include:  
1. Signed protocol and all amendments;  
2. IRB approvals for the study protocol and all amendments;  
3. All source documents and laboratory records;  
4. CRF copies;  
5. Signed ICF for both screened and enrolle d subjects; and  
6. Any other pertinent study document . 
8. STUDY MONITORING, AU DITING AND INSPECTIN G 
8.1. Study Monitoring Plan  
 
This study will be monitored according to the monitoring plan detailed below.  The investigator will 
allocate adequate time for such monitoring activities.  The Investigator will also ensure that the monitor 
or other compliance or quality assurance reviewe r is given access to all the above noted study -related 
documents and study related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and has adequate space 
to conduct the monitoring visit. A risk -based, data -driven monitoring approach will be used t o verify data 
for this trial which will also include a centralized review of data for quality, trends, consistency and 
general safety review.  A quality assurance specialist will make regularly scheduled trips to the 
investigational site to review the prog ress of the trial, study data and site processes.  At each visit, the 
Protocol S16 -00098  Confidential  Page 67 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 monitor will review various aspects of the trial including, but not limited to:  screening and enrollment 
logs; compliance with the protocol and study manual and with the principles of G ood Clinical Practice; 
completion of case report forms; source data verification; study drug accountability and storage; facilities 
and staff.  
 
During scheduled monitoring visits, the investigator and the investigational site staff must be available to 
meet with the quality assurance specialist in order to discuss the progress of the trial, make necessary 
corrections to case report form entries, respond to data clarification requests and respond to any other 
trial-related inquiries of the monitor. In additi on to on -site monitoring visits, the Sponsor -investigator  
and/or representatives will also be routinely reviewing data. Any queries identified through this review 
will be managed within the systems established for query resolution and tracking. Inquiries r elated to 
study conduct, which require further information or action will be  discussed within the study team for 
appropriate and documented escalation plans. It is expected that response to data clarification requests 
and other trial -related inquiries will  occur throughout the course of the study through regular 
communication with the site monitor, the Sponsor -investigator  or representatives, and review/entry of 
data into the electronic study database.  
 
At any time during the course of the study, representa tives of the FDA and/or local regulatory agencies 
may review the conduct or results of the study at the investigational site. The investigator must promptly 
inform Bristol Myers Squibb  of any audit requests by health authorit ies, and will provide BMS with the 
results of any such audits and with copies of any regulatory documents related to such audits.  
 
The investigator will allocate adequate time for such monitoring activities.  The Investigator will also 
ensure that the monitor or other compliance or qual ity assurance reviewer is given access to all the above 
noted study -related documents and study related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and 
has adequate space to conduct the monitoring visit.  
 
At the NYU Perlmutter Cancer Center, a ll investigator -initiated protocols are subject to a standardized 
data and safety monitoring, which includes scientific peer review, IRB review and DSMC review as well 
as internal auditing.  
 
The review of AEs and trial conduct for this trial occurs at sev eral levels:  
 
(1) Principal Investigator: Adverse events are evaluated monthly by the principal investigator in 
conjunction with the research nurses, data manager and research team.  
 
(2) DSMC, twice annually  
 
(3) Institutional Review Board (IRB): An annua l report to the IRB is submitted by the trial PI for 
continuation of the protocol. It includes a summary of all AEs, total enrollment with 
demographics, protocol violations, and current status of subjects as well as available research 
data.  
 
(4) In additio n, the quality assurance unit will monitor this trial every 6 -8 weeks, to verify  
adherence to the protocol; the completeness, accuracy and consistency of the data; and adherence  
to ICH Good Clinical Practice guidelines.  
Protocol S16 -00098  Confidential  Page 68 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 8.2. Auditing Procedure  
In addition to the routine monitoring procedures at the Laura and Isaac Perlmutter Cancer Center which 
include annual audits of all patients treated on investigator initiated trials, or by NCI/CTEP or the FDA, 
BMS, Inc. or its designees may conduct audits of clinical res earch activities of this trial in accordance 
with internal Standard Operating Procedures to evaluate compliance with the principles of Good Clinical 
Practices. BMS, Inc., its designee, or a regulatory authority may wish to conduct an inspection (during the  
study or after its completion). If an inspection is requested by a regulatory authority, the Investigator will 
inform BMS, Inc. immediately that this request has been made.  
9. ETHICAL ASPECTS  
9.1. Ethics and Good Clinical Practice  
This study must be carried out in compliance with the protocol and in accordance with the Sponsor -
investigator ’s SOPs. These are designed to ensure adherence to Good Clinical Practice (GCP), as 
described in the International Conference on Harmonisation (ICH) GCP Guideline (1996) and in 
accordance with the ethical principles underlying European Union Directive 2001/20/EC and the United 
States Code of Federal Regulations, Title 21, Part 50 (21CFR50) and Title 21, Part 312 (21CFR312).  
The protocol and any amendments and the subject informed  consent will receive IRB approval/favorable 
opinion before initiation of the study. Study personnel involved in conducting this study will be qualified 
by education, training, and experience to perform their respective tasks. This study will not use the 
services of study personnel where sanctions have been invoked or where there has been scientific 
misconduct or fraud (eg, loss of medical license, debarment).  
 
10. STUDY FINANCES  
10.1. Funding Source  
Funding for conducting the trial will be provided by BMS.  The inve stigational agent will be provided to 
patients enrolled on this study by Bristol Myers Squibb . 
10.2. Subject Stipends or Payments  
No patient or subject will receive payments or stipends for participation in this research study.  Bristol 
Myer Squibb may provide coverage for tests and/or procedures that are a part of the research study, if it is 
not covered by the subject’s insurance.  
 
11. PUBLICATION PLAN  
Any formal presentation or publication of data collected from this study will be considered for a joint 
publicati on by the Investigator(s) and the appropriate personnel of BMS. Authorship will be determined 
by mutual agreement.  
Protocol S16 -00098  Confidential  Page 69 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 BMS, Inc. must receive copies of any intended public communications of study data or results 
(eg, manuscripts, posters, abstracts and oral presentations) at least thirty (30) days in advance of their 
submission. For abstracts, this requirement can be met by providing to BMS, Inc. details about the data 
and subject matter to be disclosed if a final draft of the abstract is not available 30 day s in advance. BMS, 
Inc. will review the communications for accuracy (thus avoiding potential discrepancies with submissions 
to health authorities), verify that confidential information is not being inadvertently disclosed, and 
provide any relevant suppleme ntary information and comments.  
12. ADMINISTRATIVE REQUI REMENTS  
12.1. Institutional Review Board  
Before implementing this study, the protocol, the proposed ICF, and other information provided to 
subjects must be reviewed and approved by an IRB before study initiatio n. Any amendments to the 
protocol which need formal approval, as required by local law or procedure, will be approved by this 
committee. The IRB will also be notified of all other amendments (ie,  administrative changes)  
12.2. Protocol Amendments  
Any change or addition to this protocol requires a written protocol amendment. Amendments affecting 
the safety of subjects, the scope of the investigation or the scientific quality of the study, as well as 
administrative amendments require additional approval by the IRB . All amendments that affect the safety 
of subjects, the scope of the investigation, or the scientific quality of the study must be approved by BMS 
and the NCI CTEP prior to implementation. Examples of amendments requiring such approvals are:  
1. Increase in d rug dosage or duration of exposure of subjects  
2. Significant change in the study design (eg addition or deletion of a control group)  
3. Increase in the number of invasive procedures to which subjects are exposed  
4. Addition or deletion of a test procedure for safe ty monitoring  
These requirements for approval should in no way prevent any immediate action from being taken by the 
Principal Investigator or by BMS, Inc. in the interests of preserving the safety of all subjects included in 
the trial. If an immediate chan ge to the protocol is felt to be necessary by the Investigator and is 
implemented by him/her for safety reasons BMS, Inc. should be notified and the NYULMC IRB  should 
be informed within 10  working days.  
. 
 
. 
Protocol S16 -00098  Confidential  Page 70 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 13. REFERENCES  
 
 
1. Cancer Facts and Figures 2016. American Cancer Society. Atlanta GA. 2016.  
2. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of 
immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 
2006;90:1 –50. 
3. Brown  JA , Dorfman DM, Ma FR, Sullivan EL, Munoz O,  Wood CR, Greenfield EA, and Freeman GJ. 
Blockade of programmed death -1 ligands on dendritic cells enhances T cell activation and cytokine 
production.  J. Immunol.  170: 1257 -66. 
4. Oh, S ., J. W. Hodge, J. D. Ahlers, D. S. Burke, J. Schlom, and J. A. Berzofsky.  Selective induction of  
high avidity CTL by altering the balance of signals from APC.  J. Immunol.  170: 252 3-30. 
 
5. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its 
ligands in regulating autoimmunity and infection. Nat Immunol 2007;8(3):239 -245. 
6. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 
2005;23:515 -548. 
7. Nishimura H, Honjo T. PD -1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends 
Immunol 2001;22(5):265 -268. 
8. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD -1 immunoinhibitory  receptor by a novel 
B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 
2000;192(7):1027 -1034.  
9. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J , Garbe C, Lebbe C, Baurain JF, Testori A, Grob 
JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, 
Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD Ipilimumab  plus dacarbazine for 
previously untreated metastatic me lanoma. . N Engl J Med. 2011 Jun 30;364(26):2517 -26. 
 
10. Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, Yellin 
M, Weber JS.  Extended dose ipilimumab  with a peptide vaccine: immune correlates associated with 
clinical benefit in patients with resected high -risk stage IIIc/IV melanoma.  Clin Cancer Res. 2011 Feb 
15;17(4):896 -906.  
 
11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez  R, Robert C, 
Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette 
GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, 
Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab  in patients with metastatic 
melanoma.  N Engl J Med. 2010 Aug 19;363(8):711 -23 
 
12. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berma n DM, 
Wolchok JD Pooled Analysis of Long -Term Survival Data From Phase II and Phase III Trials of 
Ipilimumab  in Unresectable or Metastatic Melanoma. .J Clin Oncol. 2015 Jun 10;33(17):1889 -94 
 
13. Eggermont AM, Chiarion -Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert 
C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Bastholt L, Mortier 
L, Thomas L, Tahir S, Hauschild A, Hassel JC, Hodi FS, Taitt C, de  Pril V, de Schaetzen G, Suciu S, 
continued  
Protocol S16 -00098  Confidential  Page 71 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  
Testori A.  Prolonged Survival in Stage III Melanoma with Ipilimumab  Adjuvant Therapy.  N Engl J Med. 
2016  
 
14. Eggermont AM, Chiarion -Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant 
ipilimumab versus placebo after complete resection of high -risk stage III melanoma (EORTC 18071): a 
randomised, double -blind, phase 3 trial. Lancet Oncol. 2015;16:522 -30.  
Brahmer JR, Drake CG, Wollner  I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay 
TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll 
DM, Lowy I, Topalian SL. Phase I stud y of single -agent anti -programmed death -1 (MDX -1106) in 
refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.   J Clin 
Oncol. 2010 Jul 1;28(19):3167 -75.  
 
15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal 
RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen 
L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure -Kunkel M, Agrawal S, 
McDonald D, Kollia GD, Gupta  A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of 
anti-PD-1 antibody in cancer.   N Engl J Med. 2012 Jun 28;366(26):2443 -54.  
 
16. Topalian SL, Sznol M, McDermott DF, Kluger HM,  Carvajal RD, Sharfman WH, Brahmer JR, 
Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, 
Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Survival, durable tumor 
remission, and long -term safety in patients with advanced melanoma  receiving nivolumab . 
J Clin Oncol. 2014 Apr 1;32(10):1020 -30.  
 
17. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, 
Wang W, G ibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA.  Safety, efficacy, and biomarkers of 
nivolumab  with vaccine in ipilimumab -refractory or -naive melanoma . J Clin Oncol. 2013 Dec 
1;31(34):4311 -8.  
 
18. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller 
WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, 
Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, K rackhardt AM, Horak C, Lambert 
A, Yang AS, Larkin J.  Nivolumab  versus chemotherapy in patients with advanced melanoma  who 
progressed after anti -CTLA -4 treatment (CheckMate 037): a randomised, con trolled, open -label, phase 3 
trial.  Lancet Oncol. 2015 Apr;16(4):375 -84.  
 
19. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, 
Kalinka -Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiar ion-Sileni V, 
Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren -Eriksson L, Horak C, 
Sharkey B, Waxman IM, Atkinson V, Ascierto PA.   Nivolumab  in previously untreated melanoma  
without BRAF mutation.  N Engl J Med. 2015 Jan 22;372(4):320 -30.  
 
20. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, 
Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, 
Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab  
plus ipilimumab in advanced melanoma .  N Engl J Med. 2013 Jul 11;369(2):122 -33.  
 
21. Postow MA, Chesney  J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, 
continued  
Protocol S16 -00098  Confidential  Page 72 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
  
Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin 
LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.  Nivolumab  and ipilimumab versus ipilimumab in 
untreated melanoma . N Engl J Med. 2015 May 21;372(21):2006 -17.  
 
22. Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, 
Richards A, Schell MJ, Fisher KJ, Horak  CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS.  
Safety, correlative markers, and clinical results of adjuvant nivolumab  in combination with vaccine in 
resected high -risk metastatic melano ma. Clin Cancer Res. 2015 Feb 15;21(4):712 -20 
 
23. Khushalani NI, Kim Y, Gibney GT, Kudchadkar RR, Eroglu Z, Markowitz J,. Czupryn MP, Thebeau  
MS, McCormick L, Richards A, and Weber JS  Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for 
resected high -risk stages IIIC/IV melanoma (MEL)   J Clin Oncol 34, 2016 (suppl; abstr 9586)  
Protocol S16 -00098  Confidential  Page 73 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 14.  APPENDICES  
Protocol S16 -00098  Confidential  Page 74 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Appendix 1:  Imaging Methodologies  
Contrast enhanced CT or enhanced MRI are the preferred imaging modalities to be used. 
Chest  radiographs performed during the screening phase (and repeated at anytime  during the study if 
clinically indicated) may be used as supportive data, as an accessory to the CT chest scans.  
The same imaging techniques used at screening MUST be used at all subsequent time points to permit 
accurate, comparable measurement of lesions . All imaging data are to be collected on film or in digital 
format.  
CT/MRI of the Chest/Abdomen/Pelvis  
CT/MRI imaging of the chest, abdomen and pelvis is required at Screening and at each tumor assessment 
visit as indicated in Table 1, regardless of the l ocation of known prior metastases. In addition, CT/MRI 
scans must be obtained of anatomic regions not covered by the chest, abdomen and pelvic scans, in 
subjects where there is clinical suspicion of deep soft tissue metastases indicative of relapse (eg,  lesions in 
the thigh). Such additional CT/MRIs will be required at Screening only when deep soft tissue disease was 
present and was resected and must be consistently repeated at all subsequent tumor assessment visits.  
Brain MRI/CT  
Brain scans (MRI or CT) ar e required at Screening. Brain scans should be conducted during the course of 
the study as clinically indicated.  
Non-radiographic Assessments/Digital Photography  
These should be made at the sites and recorded in the source documents. Visible skin lesions indicative of 
relapse should be measured clinically and documented digitally using standardized photographic images, 
including a ruler for scale as part of the image.  
Image Acquisition Guidelines  
Similar methods of tumor assessment and similar techniques m ust be used to characterize each identified 
and reported lesion at Screening and during the Induction and Maintenance Phases. Additional 
assessments may be performed, as clinically indicated, if there is a suspicion of relapse.). Imaging -based 
evaluation i s preferred to physical examination. Helical (spiral) CT scans of neck, chest, abdomen and 
pelvis are preferred. If not available, conventional (non -helical, non -spiral CT) should be used. IV 
contrast should be used for all CT scans. If i.v. contrast is co ntraindicated, CT may be performed without 
contrast. Alternatively, MRI can be used to assess lesions that might be indicative of relapse. Subjects 
who develop contrast allergy after study enrollment may be followed by MRI for subsequent tumor 
measurements . Sections should be contiguous, similarly sized and consistent from visit -to-visit. Section 
thickness must be based on institutional standards (eg, from 5 to 8 mm; 10 mm cuts are not 
recommended). Chest radiograph, ultrasound, and PET scans are not accept able methods to routinely 
assess patients for the presence of disease for the purposes of this study.  
Protocol S16 -00098  Confidential  Page 75 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Appendix 2:  ECOG Performance Status  
ECOG PERFORMANCE STATUS  
Grade  ECOG  
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, eg, light house work, office work.  
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities. Up and about more than 50% of waking hours.  
3 Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours.  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair.  
5 Dead  
 
Oken MM, Creech RH, Tormey  DC, Horton J, Davis TE, McFadden ET, and Carbone PP. Toxicity 
and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649 -655. 
 
Protocol S16 -00098  Confidential  Page 76 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Appendix 3:  Pre-existing Autoimmune Diseases  
Subjects should be carefully questioned regarding their histor y of acquired or congenital immune 
deficiencies or autoimmune disease. Subjects with any history of immune deficiencies or autoimmune 
disease are excluded from participating in the study. Possible exceptions to this exclusion could be 
subjects with a medic al history of such entities as atopic disease or childhood arthralgias where the 
clinical suspicion of autoimmune disease is low. In addition, transient autoimmune manifestations of an 
acute infectious disease that resolved upon treatment of the infectious  agent are not excluded (eg, acute 
Lyme arthritis). Please contact the BMS Medical Monitor regarding any uncertainty over autoimmune 
exclusions.  
Diseases that may be autoimmune related include but are not limited to the following: 
Acute diss eminated 
encephalomyelitis  
Addison’s disease  
Alopecia universalis  
Ankylosing spondylitis  
Antiphospholipid antibody 
syndrome  
Aplastic anemia  
Asthma  
Autoimmune hemolytic 
anemia  
Autoimmune hepatitis  
Autoimmune 
hypoparathyroidism  
Autoimmune hypophysitis 
Autoimmune myocarditis  
Autoimmune oophoritis  
Autoimmune orchitis  
Autoimmune 
thrombocytopenic purpura  
Behcet’s disease  
Bullous pemphigold  
Celiac disease  
Chronic fatigue syndrome  
Chronic inflammatory 
demyelinating 
polyneuropathy  
Churg -Strauss syndrome  
Crohn’ s disease  Dermatomyositis  
Dysautonomia  
Eczema  
Epidermolysis bullosa 
acquista  
Gestational pemphigoid  
Giant cell arteritis  
Goodpasture’s syndrome  
Graves’ disease  
Guillain -Barré syndrome  
Hashimoto’s disease  
IgA nephropathy  
Inflammatory bowel disease  
Interstitial cystitis  
Kawasaki’s disease  
Lambert -Eaton myasthenia 
syndrome  
Lupus erythematosus  
Lyme disease - chronic  
Meniere’s syndrome  
Mooren’s ulcer  
Morphea  
Multiple sclerosis  
Myasthenia gravis  
Neuromyotonia  
Opsoclonus myoclonus 
syndrome  
Optic neuritis  Ord’s thyroiditis  
Pemphigus  
Pernicious anemia  
Polyarteritis nodusa  
Polyarthritis  
Polygrandular autoimmune 
syndrome  
Primary biliary cirrhosis  
Psoriasis  
Reiter’s syndrome  
Rheumatoid arthritis  
Sarcoidosis  
Scleroderma  
Sjögren’s syndrome  
Stiff-Person syndrome  
Takayasu’s arteritis  
Ulcerative colitis  
Vogt -Kovanagi -Harada 
disease  
Vulvodynia  
Wegener’s granulomatosis  
 
 
 
 
 
 
 
 
 
Protocol S16 -00098  Confidential  Page 77 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 Appendix 4:  Description of  Use of Blood Samples for Immun e Analyses  
 
Detection of Proliferating T cells After NIVOLUMAB  + ipilimumab  Treatment  
Two different but complementary methods (Ki -67 and propidium iodide staining) will be used to detect 
proliferation of T cells in the peripheral blood of subjects on this trial.  Pre -treatment (pheresis), and on 
weeks 5 and 9  (80 mL sam ple of blood in green top heparinized tubes on infusion days, prior to infusion) 
and week 12 follow -up (pheresis) during the trial, PBMC cells will be stained with PI, anti -CD3, anti -
CD4, anti -CD8 (T cell markers) and anti -CD56 (NK marker).  PI staining wi ll define the proportion of 
cells in S -phase, and Ki -67 staining with anti -CD3/4/8/56 will define the proliferating compartment.  
Although it is felt that the proportion of proliferating Ki -67(+) cells and the proportion of cells in S phase 
will be identic al (77), Ki -67 staining will be the “gold” standard to define the proliferating population in 
case the two parameters are in disagreement.  A value of 1.0 % Ki -67 staining will be regarded as 
minimal evidence for proliferation in subjects based on data fro m HIV subjects (77). In a recent study in 
HIV infected subjects, Ki -67 staining was found to correlate closely (r=0.90) with an in vivo detection 
technique for T cell proliferation using deuterated glucose to label the DNA sugar backbone (78).   Fresh 
PBMC  will be stained with anti -CD3 -PerCP, anti -CD4 -APC and anti -CD8 -PE (all from Becton -
Dickinson).  After washing, cells will be lysed at room temperature for 40 minutes, and stained with anti -
Ki-67 (MIB -1 from B -D) in PBS with 0.5% NP -40 and 5% FCS at room t emperature for 45 minutes. 
Cells will be washed and fixed with 1% paraformaldehyde and run directly using a FACscan flow 
cytometer (Beckman -Coulter).  All tests will be batched and run simultaneously. The definition of 
augmented proliferation for the purpo ses of this trial will be a 20% increase in the absolute proportion of 
antigen -specific, tetramer positive CD8+ T cells that stain with the Ki -67 marker. We will also assess the 
phenotype of circulating CD8 and CD4+ T cells in this study using antibodies a gainst markers including 
HLA -DR, CD25, CD44, CD45 RO/RA, CD62L, CD73, CD95, CD127, FOXp3, PD -1, CTLA -4, BTLA, 
CD160, Tim3, LAG3, VISTA, 41 -BB, OX -40, and ICOS.  
Polymorphism Analysis  
The four single nucleotide polymorphisms known to be present in CTLA -4 (79 -81) and at least six known 
for PD -1 (82, 83) will be measured by DNA PCR analysis, and a selection of 20% of the total samples 
will have the results verified by direct DNA sequencing of the relevant areas of DNA. All subjects will be 
used from the first, and the second trials and the data will be pooled to allow correlations, if any, to be 
drawn between the presence of a SNP, response, time to progression and development of autoimmunity.   
Studies on Regulatory T cells  
 We propose to study the regulatory activity of CD4+CD25+ high cells before and after NIVOLUMAB  
+ipilimumab  treatment. Peripheral blood CD4+ T cells will be sorted into CD4+CD25+ and CD4+CD25- 
populations by flow cytometry. The latter cell subset (responde rs) will be stimulated with anti -CD3 (10 
g/ml) alone or with anti -CD28 (2g/ml) and with or without IL -2 (10 IU/ml) in the presence of 
increasing numbers of sorted CD4+CD25+cells. In addition, CD4+CD25- will be stimulated with 
allogeneic mature myeloid de ndritic cells (DC), generated from PBMC with GM -CSF and IL -4 and 
matured with a cytokine cocktail (IL -6, IL -1 beta, TNF -alpha and PGE -2), in the presence or absence of 
Protocol S16 -00098  Confidential  Page 78 
Laura and Isaac Perlmutter Cancer Center  
Version 7, date 10 Nov 2017  
 CD4+CD25+. The ability of CD4+CD25+ to suppress the proliferation of CD4+CD25- to polycl onal or 
allogeneic stimulation in a 3 to 5 day proliferation assay using tritiated thymidine incorporation will be 
determined. We anticipate that CD4+CD25+ cells will exhibit suppressor activity in vitro as has been 
previously described and that NIVOLUMAB  + ipilimumab  treatment will inhibit their suppressive 
activity in either polyclonal or allogeneic proliferation reaction. We will examine whether loss of 
suppressor activity of CD4+CD25+ cells, if found, following NIVOLUMAB  + ipilimumab  treatment 
correlate s with the development of colitis or other autoimmune side effects. The suppression of allo MLR 
proliferation by isolated CD4+CD25+ is an established assay, and well -established in the principal 
investigator group.  